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ABSTRACT  
 4
 
Current concerns about the health effects of airborne particles are largely based on the results of 
epidemiological studies, suggesting effects on mortality and morbidity for cardiovascular and 
respiratory causes at very low levels of particulate matter exposure. The mechanisms behind 
these effects are still unknown, although some hypothesis have been postulated. The studies 
support the idea that inhalation of PM can instigate extra-pulmonary effects by the release of 
pro-inflammatory mediators (eg. cytokines, activated immune cells, platelets), vasculoactive 
molecules (eg. ET, histamine, microparticles) from lung-based cells; and/or by translocation of 
PM (UFPs) or particle constituents (organic compounds, metals) into the systemic circulation. 
Subsequently, these events may contribute to a systemic inflammatory state, which may in 
turn be capable of activating haemostatic pathways, impairing vascular function, and 
accelerating atherosclerosis.  
Which fraction of PM is the most harmful is still controversial, and few studies investigated 
the role of personal exposure to different fractions, in particular fine and ultrafine particles. 
 
Aims. My doctoral thesis aims at characterize the effects of PM exposure on inflammatory and 
coagulatory indices in susceptible subjects (with chronic heart diseases or chronic respiratory 
diseases), focused on the role of the fine and ultrafine particles in determining changes in these  
markers.  
 
Materials and methods. 27 healthy individuals (Healthy group), 34 individuals with chronic 
ischemic heart disease (Heart group), 18 with chronic asthma or COPD (Lung group) 
underwent a 24-hour exposure/clinical evaluation protocol during their habitual activities, both 
in the warm season (no heating period) and in the cold season (heating period). Individual 
exposure to UFPs (0.02–1 µm, Aerodynamic Diameter, D.a), fine and coarse particles number 
concentration (0.3-0.5; 0.5-1.0; 1.0-2.5; 2.5-5.0; 5.0-10 µm D.a), gravimetric PM0.5, PM1, 
PM2.5 and PM10 was assessed for each subject, along with measurement of total blood cells 
count and blood markers of inflammation [TNF-alfa, sRI- and sRII-TNF-alfa, IL-8, IL-10, hs-
CRP] and coagulation [fibrinogen, aPTT, INR, D-dimer, vWF, tPA, F1+2, closure time 
measured with PF 100 Analyzer® (PFA100 C-EPI CT e PFA100 C-ADP CT)].  
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Since the three groups had different clinical status, each group were analyzed independently 
using mixed effects models for repeated measurements to evaluate the associations between 
particles exposure and clinical parameters. Models include time varying factor (PM, 
temperature and relative humidity) and time-invariant subjects specific characteristics (age, 
gender, BMI, drug assumption). Pollution effects were expressed as percent changes by 
interquartile range (IQR) changes of PM ( Chuang K. et al. 2007).  
 
Results. The mean age for the overall studied population was 64±10 years at the beginning of 
the study and the gender was male for the 63% of individuals. 
The median (25°-75° percentiles) 24h concentration of PM10 during the no-heating period was 
35.5 (29.3-51.1) μg/m3 and during the heating period  58.0 (41.7-79.0) μg/m3. For PM2.5, the 
median concentration (25°-75° percentiles) during the no-heating period was 26.8 (21.4-37.7) 
μg/m3 and during the heating period  49.8 (33.7-66.3) μg/m3. Comparing the data from the two 
monitoring periods, the results showed a significant increase for particulate matter 
concentrations in the heating ignition power-on period. The PM10 percentage variation was 
63.4% and for PM2.5 was 85.8%. The three groups of subjects were exposed to similar PM 
concentration, except for fine particles (PM0.5, FP0.3-1 D.a), that were higher in the Healthy 
group. 
The subjects in the three groups provided different values of total leukocytes count, 
inflammatory parameters and coagulation parameters. Healthy group showed lower values of 
inflammatory markers than those in Heart and Lung groups, which in particular is 
characterized by slight higher levels of inflammatory markers and lower levels of an 
antinflammatory marker (IL-10). Concerning coagulation parameters, Heart group presented 
longer closure time (PFA-100 CT) than Lung and Healthy groups. 
The results of the mixed models in the Heart group showed significant increase in monocytes 
number associated with fine and coarse particles. The monocytes increased of 7.9% (p=0.06) 
in association with PM10. Erythrocytes number increased of 2.14% (p=0,02) in association 
with FP0.3-0.5 and of 1,9% (p=0.01) in association with CP5-10. Platelets number increased of 
6.77% (p=0.08) in association with PM0.5, and of 5.19% (p=0.08) with CP5-10, although the 
relation is slight significant.  
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In Healthy group, variations of lymphocytes number were associated with fine and coarse 
particles. The lymphocytes increased of 8,71% (p=0,01) in association with PM10, and of 
5.68% (p=0.004) in association with FP0.3-0.5.  
In the Lung group there is a negative association with monocytes and lymphocytes with fine 
and coarse particles and only with fine particles respectively. The number of monocytes 
decreased of 14,73% (p=0,01) in association with PM10, and decreased of 14.45 % (p=0.02) in 
association with FP0.3-0.5. The lymphocytes decreased of 11.48% (p=0.04) in association with 
FP0.3-0.5 .  
There were negative associations between closure time (PFA-100 C-EPI CT) and fine particles 
in Healthy group,  and between fine and coarse particles in Heart group. In Healthy group, the 
closure time was shortened of 10% (p=0.06) in association with PM1 and of 6.81 % (p=0.05) 
with FP0,5-1. In Heart group closure time was shortened of 17.84% (p=0.02) in association 
with PM1 and of 14.98 % (p=0.004) with FP0,5-1.  
In Healthy group the t-PA is positive associated with ultrafine, fine and coarse particles. The t-
PA varied of 22.47% (p=0.07) in association with PM1 and of 22.38% (p=0.05) with FP0,3-0,5   
No changes were present in the Lung Group. 
No statistical associations were found for cytokines, interleukins, hsPCR and the others 
parameters.  
 
Discussion. Investigated subjects experienced high levels of individual exposure to PM2.5 and 
PM10. In particular, exposure to PM2.5 exceeded the 24-hour mean of 25 µg/m3 suggested by 
WHO in both the investigated periods, while the limit suggested for PM10 (i.e 50 µg/m3) was 
exceeded only in cold season (WHO, 2005). Observed PM10 concentrations were similar to 
twenty four hours average reported for urban background in Europe (Larssen S. et al. 2005), 
and PM2.5 concentrations were similar to the previously reported for personal monitoring 
indoor and outdoor in Milan (Rotko T. et al. 2002).  As expected, higher levels of exposure to 
almost all particles were observed in the cold season. The great contribution of these higher 
winter levels is mainly due to particles in the accumulation mode (FP0.3-1 µm). In cold season 
the PM levels are strongly affected by the stability of the atmosphere, by the low degree of air 
convection (characteristics of the warm season), and also by the heating which is one of the 
major sources of the particles in the accumulation mode.  
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The different levels of exposure among the three groups were mainly caused by fine particles 
in the accumulation mode (FP0.3-1 µm) and the Healthy group seemed to be the higher 
exposed. An analysis of the activity of these subjects showed that they have spent more time 
outdoor than the subjects of other groups, so they were much exposed to particles from 
outdoor origin, the particles in the accumulation mode, confirming the outdoor origin of these 
particles.  
A comparative analysis of the biological data among the three groups shows that the Healthy 
group presented strongly different values from the other groups, as expected, confirming a 
great status of health of these subjects compared with the others. The Heart group showed an 
impairment of the coagulation parameters in comparison to the others, probably due to the 
characteristics of the diseases and the assumed anti-clotting therapy. The Lung group seemed 
to have an impairment of the activation of the antinflammatory markers with a persistent low 
grade condition of inflammation. 
The increase of monocytes, erythrocytes and platelets number in Heart group and 
lymphocytes number in Healthy group in association with fine and coarse particles could 
suggest an increased bone marrow activity, involving a variety of cell types, as a result of the 
effects of cytokines and chemokines from the lung that spill over into the circulation and 
trigger a cascade of inflammatory reaction signals generated in the lung. A leukocytosis 
associated with the activation of bone marrow activity was demonstrated in human exposed to 
PM, that reacted mobilizing leucocytes into circulation as a part of systemic exposure (Tan 
WC. et al. 2000; Sakai M. et al. 2004). On the other hand we observed a negative association 
between PM and monocytes and lymphocytes number in the Lung group that could be explain 
by the presence of allergic subjects in this group; the summer PM in Milan is more rich in 
pollens, endotoxins and biological materials (Camatini M. et al. 2010), so we could 
hypothesize a pro-allergic effects of no-heating PM levels, an increase of the inflammatory 
pattern during the no-heating period.  
 
The activation of the platelets aggregation capacity, measured as closure time with PF 100 
Analyzer, in Heart and Healthy groups in association with fine particles could suggest that 
particles with little aerodynamic diameter could pass directly from the alveoli to the blood and 
interact with the platelets, impairing their aggregability. Another possible mechanism of 
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platelets activation might reside in the pulmonary oxidative stress and the activation of subsets 
of white blood cells, that lead to a systemic lowering of endothelial- and platelet-derived 
nitrogen oxide and concomitant platelets activation (Brook RD et al 2008). Moreover, the 
increment of the tissue type plasminogen activator in the Healthy group in association with 
fine particles could suggest an increased thrombin generation and a reduced fibrinolytic 
activity.  
The lack of consistencies in the association with PM and cytokines and interleukins could be  
explain by the fact that we have measured these factor after about 12 hours of the higher PM 
exposure levels, missing probably the concentration peaks in the blood (they have very short 
half-life). While the lack of consistencies in the association with PM and fibrinogen and C 
reactive protein could be due to the time necessary for the ex-novo synthesis of these proteins 
in the liver, that requires an induction time of 1-2 days (Seaton A. et al. 1999, Ruckerl R. et al. 
2006).  
The strength of this study is that it is one of the few using individual monitoring of gravimetric 
and number concentration of particles. The use of fixed site monitoring stations could not be 
representative of personal exposure resulting in imprecise associations (Delfino RJ. et al. 
2008), therefore the individual monitoring is the only way to measure the real exposure of the 
subjects. A limitation of our study is that we enrolled a small number of subjects with different 
pathologies and drug therapies, that had a large impact on the biological parameters. Moreover 
we monitored these subjects only twice, resulting in few data for each subjects. Despite of 
these limitation, this work supports the hypothesis that exposure to PM results in a systemic 
inflammatory response, characterized by stimulation of bone marrow activity, that could 
increase the blood coagulability. It could also support the hypothesis that small particles may 
translocate form the lung into circulation and directly activate platelets and blood vessels. 
Together these mechanisms may account for the increase of cardiovascular events associated 
with episodes of air pollution.  
 
Conclusion. The results suggest that PM exposure could contribute to the risk of 
cardiovascular events, in particular in elderly and subjects with cardiovascular diseases. Since 
there are evidences linking PM air pollution exposure and cardiovascular mortality and 
morbidity, may we consider PM as a risk factor for cardiovascular diseases or not? Particulate 
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matter exposure is ubiquitous, it may continuously enhance acute cardiovascular risk among 
susceptible people worldwide; moreover it may further elicits numerous adverse biological 
responses that could augment cardiovascular risk over the long term. Therefore, PM could be 
surely considered as a factor that modify and contribute to cardiovascular mortality and 
morbidity.  
Despite the huge amount of studies about health effects of PM exposure, some issues remain 
open: to define the role of particles with different aerodynamic diameters and their chemical 
composition; to characterize the contribution of other co-pollutants (ozone, nitrogen dioxide, 
sulphur dioxide); to assess the importance of regional and intra-city differences in composition 
and combination of pollutants; to better define the susceptible subjects and define 
recommendations to help to reduce PM exposure; and finally to define whether there is a safe 
PM threshold concentration that eliminates both acute and chronic effects in susceptible 
subjects but also in general population. 
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1 INTRODUCTION 
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Air pollution is one of the primary health emergencies all over the word, and the Particulate 
Matter (PM) is one of the more relevant pollutant according to its toxicological pattern. The 
WHO estimated that PM contributes to approximately 800 000 premature deaths per year, 
ranking it as the 13th leading cause of worldwide mortality (WHO, 2002). Hence, the airborne 
PM appears to be an important modifiable factor that affects the public health on a global 
scale.  
Cohort and time series studies have shown that environmental exposure to PM is associated 
with both acute and chronic cardiovascular and respiratory effects, that are more relevant 
among susceptible subjects such as the elderly, individuals with COPD and asthma, recent 
myocardial infarction, ischemic heart disease, hypertension, diabetes and obesity.  
The association between PM and health effects appears to be more evident as particle size gets 
smaller because of the characteristics of the smaller particles (higher number concentration, 
better lung deposition, larger surface area).  
Although controlled human exposure and human panel studies have been conducted in order 
to identify the mechanisms underlying the epidemiologic studies, the exact mechanisms 
linking the inhalation of ambient particulate matter and increased risk of cardiovascular or 
respiratory events remain unclear.  
I had looked at susceptible groups (subjects with chronic ischemic heart disease, with chronic 
asthma or COPD) and subjects without diagnosis of the afore mentioned diseases, living in the 
urban area of Milan, to provide insight into the ways in which PM individual exposure, during 
warm and cold season, may cause alteration in inflammatory and coagulatory haematological 
parameters. 
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1.1 PARTICULATE MATTER 
1.1.1 DISTRIBUTION 
 
Particulate matter (PM) is the general term used for a mixture of solid particles and liquid 
droplets found in the air. These suspended particles vary in size, composition and origin, so 
that it is convenient to classify particles by their aerodynamic properties because they (WHO, 
2003):  
 govern the transport and removal of particles from the air; 
 govern their deposition within the respiratory system; 
 are associated with the chemical composition and source of particles. 
 
These properties are summarized by the aerodynamic diameter, that is the size of a unit-
density sphere with the same aerodynamic characteristics. The aerodynamic diameter is 
usually called simply particles size. 
Aerosol scientists use three different approaches or conventions in the classification of 
particles by size (EPA, June 2003): 
1. Modes, based on the observed size distributions and formation mechanisms; 
2. Cut point, usually based on the 50% cut point of the specific sampling device, 
including legally specified, regulatory sizes for air quality standards; 
3. Dosimetry or occupational health size, based on the entrance into various 
compartments of the respiratory system. 
 
Whereas, among the common people the most known classification method is the cut point, 
which divided the particles into “classes” according to their dimension and quantify their 
presence in the air with mass expressed as microgram per cubic meter (µg/m3). 
 
MODAL 
The modal classification was proposed first by Whitby in 1978. Whitby observed that the size 
distribution typically had three peaks which he called “modes”. The entire size distribution 
could be characterized by a trimodal model consisting of three additive log-normal 
distributions. The peak between 5 and 30 μm was named the coarse particles mode; the mode 
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with a peak between 0.15 and 0.5 μm was called the accumulation mode; the mode with a 
peak between 0.015 and 0.04 μm was called the transient nuclei or Aiken nuclei range, 
subsequently shortened to the nuclei mode. An idealized size distribution showing modes and 
formation mechanisms is shown in the Figure 1. 
Figure 1 An idealized size distribution, as might be observed in traffic, showing fine and coarse particles 
an the nucleation, Aitken, and accumulation modes that comprise fine particles. Also shown are the major 
formation and growth mechanisms of the four modes of atmospheric particles (EPA, August 2004) 
 
 
The Nucleation Mode is freshly formed particles with diameters below 10nm, observed during 
active nucleation events. The lower limit, where particles and large molecule overlap, is 
uncertain. The Aitken Mode contains larger particles with diameter between 10 and 100 nm. 
The Aitken mode may results from growth of smaller particles or nucleation from higher 
concentrations of precursor. The Accumulation Mode includes particles with diameter from 
about 0.1 μm to just above the minimum in the mass or volume distributions which usually 
occurs between 1 and 3 μm. Accumulation-mode particles normally do not grow into coarse 
mode. Nucleation-mode and Aitken-mode particles grow by coagulation (two particles 
combining to from one) or by condensation (low-equilibrium vapour pressure gas molecule 
condensing on a particle) and “accumulate” in this size range. 
The Coarse Mode or Coarse Particles are particles with diameters mostly greater than 1 or 3 
μm. These particles are usually formed by mechanical break-up of larger particles or bulk 
material. 
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The Fine particles are particles including nucleation, Aitken and accumulation mode. These 
particles are generated during combustion or formed from gases. 
The Ultrafine particles are that portion of fine particles with diameter below about 0.1 μm 
(100 nm), for example Aitken and nucleation modes. 
 
SAMPLER CUT POINT 
Another way to define particle size is to refer at size-selective sampling; size-selective 
sampling refers to the collection of particles below or within a specific aerodynamic size 
range. Size fraction is usually specified by the 50% cut point size; for example, PM2.5 refers to 
particles collected by sampling device that collects 50% of the 2.5 μm particles and rejects 
50% of 2.5 μm particles. However, size fractions are defined, not merely by the 50% cut point, 
but by the entire penetration curve.  
An idealized distribution with the normally observed division of ambient aerosol into fine-
mode particles, coarse particles and the size fractions collected by the Wide Range Aerosol 
Classifier (WRAC), Total Suspended Particles (TSP), PM10, PM2.5 and PM10-2.5 samplers  is 
shown in Figure 2.  
Figure 2. An idealized distribution of ambient particulate matter showing fine-mode particles and coarse-
mode particles and the fractions collected by size-selective samplers. (EPA, June 2003) 
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1.1.2 FORMATION AND SOURCES OF PARTICLES 
 
Particles are made up of different chemical components. The major components, or species, 
are carbon, sulphate and nitrate compounds, crustal materials such as soil and ash. The 
different components that make up particle pollution come from specific sources and are often 
formed in the atmosphere.  
Particulate matter includes both primary PM, which is directly emitted into the air, and 
secondary PM, which is formed indirectly from fuel combustion and other sources. Generally, 
coarse particles are made up of primary particles, while fine particles is dominated by 
secondary particles. 
The coarse fractions are mechanically produced by the break-up of larger solid particles. 
These particles can include wind-blown dust from agricultural processes, uncovered soil, 
unpaved roads or mining operations. Traffic produces road dust and air turbulence that can stir 
up road dust. Near coasts, evaporation of sea spray can produce large particles. Pollen grains, 
mould spores, and plant and insect parts are all in this larger size range.  
The fine fractions are largely formed from gases. The smallest particles, less than 0.1 μm, are 
formed by nucleation, that is, condensation of low-vapour-pressure substances formed by 
high-temperature vaporization or by chemical reactions in the atmosphere to form new 
particles (nuclei). Four major classes of sources with equilibrium pressures low enough to 
form nuclei mode particles can yield particulate matter: heavy metals (vaporized during 
combustion), elemental carbon (from short C molecules generated by combustion), organic 
carbon and sulphates and nitrates. 
Sub micrometre-sized particles can be produced by the condensation of metals or organic 
compounds that are vaporized in high-temperature combustion processes. They can also be 
produced by condensation of gases that have been converted in atmospheric reactions to low-
vapour-pressure substances. For example, these particles could include sulphates formed from 
sulphur dioxide emissions from power plants and industrial facilities, or nitrates formed form 
nitrogen oxide emissions from cars, truck, and power plants, or carbon formed from reactive 
organic gas emissions from cars, trucks, industrial facilities, forest fires, and biogenic sources 
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such as trees. Secondary sulphate and nitrate particles are usually the dominant component of 
fine particles. 
In the atmosphere, coarse and fine particles behave in different ways. Larger coarse particles 
may settle out from the air more rapidly than fine particles and usually will be found relatively 
close to their emission sources. Fine particles, however, can be transported long distance by 
wind and can be found in the air thousands of miles from where they were formed. 
The contribution of different sources of PM10 in Lombardy region is presented in Figure 3 
Figure 3. Emissions in Lombardy region for 2007 (adapted from ARPA Lombardia, Inemar, INventario 
delle EMissioni ARia nel 2007,public review http://ita.arpalombardia.it/ITA/inemar/regione.htm) 
Combustion in energy production and transformation industries
Non industrial combustion plants
Combustion in manufacturing industries
Production processes
Extraction and distribution of fossil fuel
Solvent and other product use
Road transport
Other mobile sources and machinery
Waste treatment and disposal
Agricolture 
Other sources and sinks
 
 
Ultrafine particles are the result of nucleation of gas phase species to form condensed phase 
species with very low equilibrium vapour pressure. In the atmosphere there are four major 
classes of substances that yield particulate matter with equilibrium vapour pressures low 
enough to form nuclei mode particles: heavy metals, elemental carbon (EC) or soot, organic 
carbon (OC), sulphates. 
Nuclei mode particles of metal oxides or other metal compounds are generated when metallic 
impurities in coal or oil are vaporized during combustion and the vapour undergoes 
nucleation. Metallic ultrafine particles also may be formed from metals in lubricating oil or 
fuel additives that are vaporized during combustion of gasoline or diesel fuels.  
EC particles are formed primarily by condensation of C2 molecules generated during the 
combustion process. Recent smog chamber studies and indoor experiments show that 
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atmospheric oxidation of certain organic compounds found in the atmosphere can produce 
highly oxidized organic compounds with an equilibrium vapour pressure sufficiently low to 
result in nucleation. Sulphuric acid molecules are generated in the atmosphere by conversion 
of sulphur dioxide (SO2) to H2SO4. As H2SO4 is formed, it can either nucleate to form new 
ultrafine particles, or it can condense on existing ultrafine or accumulation mode particles. 
Vehicle engine exhaust may include all these substances. Ultrafine particles are observed  in 
the emissions from spark, diesel, and jet engines. In these cases it seems likely that elemental 
carbon, organic compounds, ammonia and sulphuric acid from sulphur in the fuel, as well as 
metal additives in the fuel or fuel oil, may contribute to the formation of ultrafine particles.  
The presence of metals (in particular Fe and/or transitional metals) and acid compounds on the 
surface of the UFPs could have an important role in the determination of the biological effects.  
Some scientists argue that ultrafine particles may lead to some health effects may be 
associated with particle number or particle surface area. The more the dimension decreases the 
more the surface area increases, hence the ultrafine particles exhibit a greater surface area than 
the larger particles with the same mass. Increasing of the surface area leads to an increasing 
also of the proportion of atoms/molecules that are on the surface in comparison of those in the 
internal part. The increasing of the ratio surface/volume could lead to an increasing of the 
superficial energy that could make the particles biologically more reactive (Oberdoster G. et 
al. 2005b).  
1.1.3 DEPOSITION OF PARTICULATE MATTER 
 
Deposition of inhaled PM depends primarily on exposure concentrations, particle 
characteristics (size, shape, electrical charge, density and hygroscopicity), anatomy of the 
respiratory tract (lung size, airway branching pattern, airway diameters, lengths and frequency, 
depth and flow rate of breathing), tidal volume and breathing pattern.  
Larger particles (>10µm) are mainly deposited in the extrathoracic part of the respiratory tract 
(above the larynx) and the main proportion of particles of 5–10 µm in aerodynamic diameter 
are deposited in the larger conductive airways. Particles of between 2.5 µm and 5 µm are 
deposited in the smaller conductive airways in proximity to the fine airways (respiratory 
bronchioles), with normal nasal breathing. Changing from nasal breathing to mouth breathing, 
the regional deposition pattern changes markedly, extrathoracic deposition being reduced and 
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tracheobronchial and pulmonary deposition enhanced. During mouth breathing, fine particles 
(< 2.5 µm) are deposited primarily in the pulmonary region; between about 3 and 5 µm 
significant deposition in both the pulmonary and the tracheobronchial regions occurs  (Figure 
4) (WHO, 2004). The proportion of mouth breathing to nose breathing increases with exercise 
and conversation. 
An important observation is that large particles ( >2 µm aerodynamic diameter) are not 
deposited uniformly in the airways, but that there are prominent deposition “hot spots” at 
airway bifurcation and other airway surfaces directly downstream of high-velocity air flows. 
Studies have shown that also smaller particles that penetrate deeply into the lung tend to be 
deposited preferentially near airway bifurcation (Lippmann M, 1994). 
There are other factors that affect the total and regional respiratory tract particle deposition: 
ventilation rate, gender, age and respiratory disease status. In general, because of faster 
breathing rates and likely smaller airway size, women have a greater deposition of inhaled 
particles than men in upper tracheobronchial airways, but somewhat lower alveolar region 
deposition than for men. Overall, given that children have smaller lungs and higher minute 
volumes relative to lung size, they likely receive greater doses of particles per lung surface 
area than adults for comparable ambient PM exposures. This and the propensity for young 
children to generally exhibit higher activity levels and associated higher breathing rates than 
adults, likely contribute to enhanced susceptibility to ambient particle effects (EPA, 2003).  
Altered PM deposition patterns due to respiratory disease status may put certain groups of 
adults (including some elderly) and children at greater risk for PM effects. One of the disease 
that could affect the deposition pattern is chronic obstructive pulmonary disease (COPD); the 
pathophysiologic characteristics of it contribute to more heterogeneous deposition patterns and 
differences in regional deposition. People with COPD tend to breath faster and deeper than 
those with normal lungs (i.e about 50% higher resting ventilation) and had about 50% greater 
deposition than age-matched healthy adults under typical breathing conditions, with average 
deposition rates 2.5 times higher under elevated ventilation rates (EPA, 2003) 
 
Particle Clearance and Translocation  
Particles depositing on airway surfaces may be cleared from the respiratory tract completely or 
translocated to other sites within this system by regionally specific clearance mechanisms 
(EPA, 2003). Insoluble particles deposited on ciliated airways are generally cleared from the 
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respiratory tract by mucociliary activity in 24-48 hours. All of the conditions that could affect 
this activity, such as chronic sinusitis, bronchitis, rhinitis, bronchial carcinoma, asthma, COPD 
and various acute respiratory infections, could bring to an increase of the retention of 
deposited particle material and thereby, to arise the probability of toxic effects from inhaled 
ambient PM components. 
Soluble particles in the tracheobronchial region are absorbed mostly into the blood and some 
by mucociliary transport. Although tracheobronchial clearance is generally fast, the slow 
component of this clearance (likely associated with bronchioles <1mm diameter) retains 
deposited particles for more than 24 hours and has clearance half-times of about 50 days 
(EPA, 2003). 
Clearance of particles from the alveolar region by alveolar macrophages and their mucociliary 
transport is usually rapid (< 24 h). A small proportion of the particles are transported to cilial 
airways and cleared by mucociliary clearance. A larger proportion is cleared by absorptive 
pathways, which include direct penetration into epithelial cells with transport to the 
mucociliary escalator or to the interstitial space, transport through the epithelial cell wall by 
transcellular and paracellular pathways, phagocytosis and destruction by the phagocytic 
system, or transport to lymphatics (Squadrito GL et al, 2001). Penetration of uningested 
particles into the interstitium increases with increasing particle load and results in increased 
translocation to lymph nodes. Soluble particles, that aren’t absorbed quickly into the blood 
stream and traslocated to extrapulmonary organs (e.g. the heart) within minutes, may also 
enter the lymphatic system. Translocation into the lymphatic system is quite slow, and 
elimination from lymph nodes even slower (half-times estimated in decades).  
Alveolar region clearance rates are decreased in human COPD sufferers and slowed by acute 
respiratory infections, and the viability and functioning of alveolar macrophages are reduced 
in human asthmatics. These observations suggest that persons with asthma or acute lung 
infections are likely at increased risk for ambient PM exposure effects.  
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Figure 4 Deposition probability of inhaled particles in the respiratory tract according to particle size 
(WHO, 2004) 
 
 
 
 
1.2 EPIDEMIOLOGICAL STUDIES  
 
Current concerns about the health effects of airborne particles are largely based on the results of 
epidemiological studies, suggesting effects on mortality and morbidity at very low levels of 
exposure of particulate matter. A wide amount of epidemiological studies all over the world 
have evidenced that the day variations of the concentration of fine and ultrafine particles in the 
air of the city areas are associated to variation of the population morbidity and mortality. 
Epidemiological studies can be separated into those that have investigated the health effects of 
acute exposure and those of chronic exposure. In the studies related to the adverse effects of 
short-term exposure, population-wide changes in acute outcomes (mortality, symptomatology, 
hospitalization, and health-care visits) are linked to short-term variations (in terms of days) in 
ambient pollutant concentrations. Studies on health effects of long-term exposure have involved 
analysis of data (e.g. total mortality) from large cohorts from multiple geographic locations that 
differ in the average chronic ambient concentrations and mixtures of air pollutants. 
The acute effects of air pollution are generally investigated by time-series and case-crossover 
studies that explore the association between daily changes in health outcomes (e.g. mortality) 
in relation to day-to-day variations in ambient air pollution concentrations. The sum of the 
current evidence supports the findings of a review that demonstrated that short-term elevation 
in daily PM levels leads to a greater absolute risk for cardiovascular disease (CVD) related 
mortality than for other causes (69% increase in absolute mortality rate for CVDs compared 
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with 28% for pulmonary diseases) (Pope CA. 2000). To address concerns about city selection 
bias, publication bias, influence of co-pollutants, several large multicity daily time-series 
studies have been conducted worldwide. Two of the largest were the National Morbidity, 
Mortality, and Air Pollution Study (NMMAPS) in the United States ( Samet JM. et al. 2000; 
Dominici F. et al. 2003) and the Air Pollution and Health: a European Approach (APHEA-2) 
project (Katsouyanni K. et al. 2001).These studies produced remarkably consistent results. 
The NMMAPS observed outcomes in 50 million people in the 20 largest cities in the United 
States. Average mortality rates were independently associated with particle concentrations the 
day before death. Each 10 μg/m3 elevation in PM10 was associated with an increase of 0.21% 
(± 0.06 SE) and 0.31% (± 0.09 SE) for daily all-cause and cardiopulmonary mortality, 
respectively. The NMMAPS investigators reported no differences among various lag time 
periods from to 2 days and therefore based their estimates solely on the prior 24-hour period 
(1-day lag).  
The APHEA-2 study demonstrated slightly more robust associations between adverse health 
outcomes and air pollution. For 43 million people in 29 European cities, the estimated increase 
in daily mortality was 0.6% (95% CI 0.4% to 0.8%) for each 10 μg /m3 increase in PM10. 
Cardiovascular deaths were increased by 0.69% (95% CI 0.31% to 1.08%) (Zanobetti A. et al. 
2003). APHEA-2 based estimations on average particle concentrations the day of and 1 day 
before observed health outcomes (a day exposure time window).  
Additional analyses of the APHEA-2 mortality data, based on lag periods up to 40 days, found 
that the risk of adverse health effects was associated with air pollution more than doubled (eg, 
1.97% increase in cardiovascular mortality [95% CI 1.38% to 2.55%] per 10 μg/m3 elevation 
PM10) (Zanobetti A. et al. 2003). This finding indicated that the increase in cardiopulmonary 
mortality was not simply the result of “harvesting” (also called mortality displacement),  
which refers to the advancement of death by no more than a few days for severely ill 
individuals (Brook RD. et al. 2004). 
In attempt to evaluate the coherence of multicity studies across continents, the Air Pollution 
and Health: A Combined European and North America Approach (APHENA) study analyzed 
data from APHEA, NMMAPS and Canadian studies (Samoli E. et al. 2008). The combined 
effect on all-causes mortality ranged from 0.2% to 0.6% for 10 μg/m3 in daily elevation of 
PM10, with the largest effects observed in Canada. Among individuals older than 75 years, the 
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effects were greater for cardiovascular mortality than for overall and pulmonary mortality 
(0.47% to 1.30%). Higher NO2 levels were associated with larger PM10 effects on mortality, 
particularly in Europe. Finally, there appeared to be no lower-limit threshold below which 
PM10 was not associated with excess mortality across all regions.  
Some time series studies were conducted also in Asia and they have confirmed increases in 
cardiovascular mortality related to short term PM exposure in China (Wong CM. et al. 2008a) 
and in several Asian cities (Wong CM. et al. 2008b).  
The overall evidence from time-series analysis confirmed the association between increased 
mortality in occurrence of increased PM10 and PM2.5. A meta-analysis has estimated that 
increased daily mortality due to a 10μg/m3 elevation in PM2.5 in the previous 1 to 5 days is 
approximately equal to a 0.4% to 1.0% (Brook RD. et al. 2010) .  
The EpiAir Project has investigated the relationship between air pollution (PM10, NO2, O3) 
and all natural mortality, as well as cardiac, cerebrovascular and respiratory in 10 Italian cities. 
Specific issues were addressed on the latency of the effects and the susceptibility (Stafoggia 
M. et al. 2009). Short-term effects of PM10 on mortality have been detected for all the groups 
of causes, with a latency ranging from lag 0 for cerebrovascular mortality to lag 0-3 for 
respiratory mortality. The elderly subjects were especially vulnerable to the effects of 
particles. 
 
Effects of long-term exposure to PM on mortality are also of concern. Although short-term 
changes in PM concentrations have harmful health effects, long term exposure may have a more 
relevant clinical health effect on lung cancer and cardiovascular morbidity and mortality.  It has 
been estimated that long-term exposure to moderate levels of fine PM can be associated with a 
reduction in life expectancy of up to several months.  
Data on chronic effects of airborne particulate matter on mortality comes from cross-sectional 
studies, comparing air pollution exposure and mortality rates between locations, and from cohort 
studies documenting the mortality experience of differentially exposed subjects over time.  
Dockery and collaborators (Dockery DW. et al. 1993) followed a cohort of more than 8000 
adults living in six US cities (Harvard Six Cities study) with varying levels of air pollution 
exposure for periods of 14–16 years, between 1974 and 1991. After adjustment for age, sex, 
smoking, education, occupational exposure and body mass index, a significant relationship was 
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found between exposure to fine particles and lung cancer and cardiopulmonary mortality. The 
closest association was found for PM2.5 and sulphate; the estimated effect was a mortality-rate 
ratio of 1.26, comparing the most polluted city (Steubenville, OH) with the least polluted city 
(Portage, WI). 
An analysis of mortality occurring on low- and high-pollution days conducted on the data from 
Philadelphia showed a disproportionate increase in mortality among the elderly (Schwartz J. 
1994). Mortality due to chronic lung disease and cardiovascular disease was also 
disproportionally increased. Interestingly, respiratory conditions were also more often 
mentioned on death certificates as contributing causes to cardiovascular deaths on high-pollution 
days. An analysis of location of death revealed that deaths outside the hospital were 
disproportionally increased as compared to death of hospitalized patients. This pattern is very 
similar to the pattern of mortality seen during and following the 1952 London smog (WHO, 
2001). 
An analysis from the Harvard Six Cities study was published addressing the question of whether 
fine particulate mass (PM2.5) is a better predictor of mortality than coarse particulate mass 
(Schwartz J. et al. 1996). The results indicate that mortality is strongly associated with PM2.5 but 
not with coarse mass. Because of the high correlation between PM2.5 and PM10, mortality was 
also strongly associated with PM10, and the results of this particular analysis suggest that the 
associations between PM10 and mortality observed in other studies may very well be due to the 
effects of fine rather than coarse particulate mass. The pooled estimate was a relative risk of 
1.015 (95% confidence limits 1.011 to 1.019) for each 10 µg/m3 increase in PM2.5.  
An extended analysis of the US Six Cities Study was performed by Laden (Laden F. et al. 2006), 
that has extended the mortality follow-up for an additional 8 years, and has found the similar 
association between PM2.5 and all-cause and CVD mortality. Moreover, the reduction in PM2.5 
concentrations for the extended follow-up period was associated with a reduced mortality risk.  
Pope and collaborators (Pope CA. et al. 1995) analysed data from a large cohort study conducted 
by the American Cancer Society since 1980 (ACS study). Pollution data from 151 US 
metropolitan areas were linked to 8 years of follow-up data from about 500 000 subjects. After 
adjustment for age, sex, race, active and passive smoking, occupational exposure, education, 
body mass index and alcohol intake, a significant association between fine particulate air 
pollution exposure and survival emerged. The primary results showed that each 10 μg/m3 
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increase in annual PM2.5 mean concentration was associated with increases in all-causes, 
cardiopulmonary, and lung cancer mortality of 4%, 6% and 8% respectively. The relationship 
between PM2.5 and adverse effects was linear and without a discernible lower “safe” threshold. 
Comparing the highest polluted area with the lowest polluted area, an adjusted mortality-rate 
ratio of 1.17 was found for PM2.5. 
An extended analysis of the ACS study was conducted to emphasize the control for the effects 
of other covariates and risk factors (Pope AC. et al. 2002). This analysis has confirmed the 
elevated mortality risk more strongly associated with PM2.5 than PM10 and gaseous pollutants 
(except SO2).  
In a subsequent analysis of the ACS study (Pope CA. et al. 2004), the investigators reported PM-
mortality associations with the specific cause of death; a statistically robust association between 
PM2.5 and overall cardiovascular mortality was confirmed for 10 μg/m3 increase in long-term 
exposure (RR 1.12, 95% CI 1.08 to 1.15). The single largest increase in risk was for ischemic 
hearth disease (RR 1.18, 95% CI 1.14 to 1.23), which also accounted for the largest proportion 
of deaths. In addition, the risk for arrhythmia, hearth failure, or cardiac arrest mortality was also 
increased (RR 1.13, 95% CI 1.05 to 1.21). 
In a recent analysis of the Adventist Health Study of Smog (AHSMOG) fatal coronary heart 
disease was significantly associate with PM2.5 among female but not male (Chen LH. et al. 
2005). The observation that women may be at special risk from PM exposure is confirmed by 
other studies (Women’s Health Initiative Study, the German women cohort, the intracity Oslo 
study) (Miller KA. et al. 2007, Gehring U. et al. 2006, Naess Ø. et al. 2007). So, the women 
seem to be a part of the susceptible population. Susceptible population include elderly, obese, 
individuals with low education or socioeconomic status, individuals with diabetes, with chronic 
cardiac disease and chronic respiratory disease (Zanobetti A. et al. 2000; O’Neil MS. et al. 2005; 
Sullivan KH. et al. 2005; Zeka A. et al. 2006; Halonen J. et al. 2008; Ostro BD. et al. 2008). In 
short-term studies, elderly subjects, and subjects with pre-existing heart and lung disease were 
found to be more susceptible to effects of ambient PM on mortality and morbidity; in panel 
studies, asthmatics have been shown to respond to ambient PM with more symptoms, larger 
lung functions changes and with increased medication use than non-asthmatics. In long term 
studies, it has been suggested that socially disadvantaged and poorly educated populations 
respond more strongly in terms of mortality (WHO, 2003). The APHENA study of European 
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and North American cities recently confirmed that elderly and unemployed individuals are at 
greater risk of short-term PM exposure (Samoli E. et al. 2008). Two cohort studies have shown 
that a greater body max index enhances the susceptibility for PM, at least in women (Miller KA. 
et al. 2007, Puett RC. et al. 2008). 
1.3 PANEL AND EXPERIMENTAL STUDIES 
 
A large amount of epidemiological studies have shown the association between variations of 
PM concentrations in urban air and variations of daily mortality and morbidity. The increase 
of mortality has been associated with both cardiovascular and respiratory harmful effects. 
These cardiovascular effects are acute (some hours after the exposure), latest and chronic (at 
least some days after the exposure); the acute effects seem to be related to a direct action of 
the PM on blood, circulation and lungs; while the latest ones are the consequence of the 
inflammation, at first pulmonary and subsequently systemic, that could active the haemostasis, 
influence the vascular functions and accelerate the atherosclerosis (Brook R.D. et al., 2004). 
Over the last several years, many studies have been conducted to understand the 
pathophysiological mechanisms of health-related PM effects; some of these have investigated 
changes in respiratory parameters, others in cardiovascular system, others both. 
 
Studies related to respiratory changes 
One of the most important studies is the panel study conducted in Erfurt, Germany. This study 
has investigated the association between particulate air pollution and asthma medication use 
and symptoms among  53 adult asthmatics in winter 1996/1997. The exposure was assessed 
measuring number concentrations of ultrafine particles and mass concentrations of fine 
particles. The associations between ambient particle concentrations and the prevalence of 
inhaled β2-agonist, corticosteroid use and asthma symptoms, were analysed separately with 
logistic regression models, adjusting for trend, temperature, weekend, holidays, and first order 
autocorrelation of the error. Cumulative exposures over 14 days of ultrafine and fine particles 
were associated with corticosteroid use; β2-agonist use was associated with 5-day mean 
number concentrations of ultrafine particles and mass concentrations of fine particles. The 
prevalence of asthma symptoms was associated with ambient particle concentrations. The 
results suggested that reported asthma medication use and symptoms increase in association 
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with particulate air pollution and gaseous pollutants such as nitrogen dioxide (von Klot S. et 
al. 2002). 
Pope CA. and collaborators have explored a possible pathophysiological pathway: transient 
declines in blood oxygenation and/or changes in cardiac rhythm following particulate 
exposure. In this study, blood oxygen saturation using pulse oximetry (SpO2) and pulse rate 
were measured daily on a panel of 90 elderly subjects during the winter of 1995-1996 in Utah 
Valley. Associations of SpO2 and pulse rate with respirable particulate pollution (particles 
with an aerodynamic diameter ≤ a nominal 10 μm) were evaluated. The results showed a little 
evidence of pollution-related hypoxia and alterations in pulse rate, that could reflect cardiac 
rhythm changes and may be part of the pathophysiology linking particles to cardiopulmonary 
mortality (Pope CA. et al. 1999). 
Other authors have studied the health effects on children as a susceptible population. Timonen 
KL. and collaborators investigated how daily variations in ambient air pollution, especially in 
particles, during the cold of winter affect repeated measurements of baseline lung function and 
exercise induced bronchial responsiveness among primary school children with chronic 
respiratory symptoms. 33 children took part in exercise challenge tests conducted outdoors in 
a school yard in the centre of Kuopio, Finland. Spirometric lung functions were measured 
indoors before the exercise, and 3 and 10 minutes after. Daily mean concentrations of PM10, 
black smoke, NO2, CO, SO2, and particle size and numbers were monitored at a nearby fixed 
monitoring site. 
Increased concentrations of black smoke, PM10, particle numbers, NO2, and CO were 
consistently associated with an impairment of baseline lung functions [forced vital capacity 
(FVC) and forced expiratory volume in 1 second (FEV1)] (Timonen KL. et al. 2002). 
 
Studies related to cardiovascular changes 
Some studies have highlighted the effects on hearth function. Pekkanen J. and collaborators 
have assessed the associations between levels of the three main modes of urban aerosol 
distribution and the occurrence of ST-segment depressions during repeated exercise tests. 
Repeated biweekly sub maximal exercise tests were performed during 6 months among 45 
adult subjects with stable coronary heart disease in Helsinki, Finland. Simultaneously, particle 
mass of PM2.5 and the number concentrations of ultrafine particles and accumulation mode 
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particles were monitored at a central site. Levels of particulate air pollution 2 days before the 
clinic visit were significantly associated with increased risk of ST-segment depression during 
exercise test. The association was most consistent for measures of particles reflecting 
accumulation mode particles (odds ratio 3.29; 95% CI, 1.57 to 6.92 for accumulation mode 
and 2.84; 95% CI, 1.42 to 5.66 for PM2.5), but ultrafine particles also had an effect (odds ratio 
3.14; 95% CI, 1.56 to 6.32), which was independent of PM2.5 (Pekkanen J. et al. 2002).  
Some studies have assessed whether PM-related deaths may be a consequence of alterations in 
the blood, secondary to pulmonary inflammation caused by the action of fine particles on 
alveolar cells, by repeatedly measuring haematological factors and relating them to 
measurements of exposure to airborne particles. In an early study, Seaton and collaborators 
have investigated 112 individuals aged up to 60 years in two UK cities providing repeated 
blood samples over 18 months and measuring, each three day period prior to blood sampling, 
the exposure at PM10 with a mathematical model based on activity diaries and comparative 
measurements of PM10 at multiple sites and during a variety of activities. They showed that 
the changes in haemoglobin adjusted for albumin suggest that inhalation of some component 
of PM10 may cause sequestration of red cells in the circulation. They also proposed that an 
action of such particles either on lung endothelial cells or on erythrocytes themselves may be 
responsible for changing red cell adhesiveness (Seaton A. et al, 1999). 
Blood parameters were measured also in the MONICA study (MONItoring of trends and 
determinants in CArdiovascular disease). The first MONICA survey was carried out on 4022 
subjects in Augsburg (Germany) during the winter 1984/1985 while an air pollution episode 
occurred throughout Central Europe; blood collected during this period has been compared to 
blood collected other sample days in the 1984/1985 survey and to follow-up periods for the 
same individuals. The results were an increased risk of extreme values of plasma viscosity 
observed in both men and women. The authors assumed that altered blood rheology due to 
inflammatory processes in the lung that induce an acute-phase reaction might therefore be part 
of the pathological mechanisms linking air pollution to mortality (Peters A. et al, 1997). In 
1987/1988, participants in the first MONICA survey were re-examined: the levels of C-
reactive protein were measured by a high sensitivity assay in serum samples of 631 men aged 
45 to 64 years. At ambient concentrations of pollution, as noted during the 1985 air pollution 
episode, the odds of observing C-reactive protein concentrations above 5.7 mg/l (>90th 
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percentile) tripled, and increases of 26 μg/m3 total suspended particles (mean of  5 days) raised 
the odds of C-reactive protein levels 50% above the 90th percentile. The conclusion is that the 
exposure to current levels of particulate matter in the atmosphere elicits an acute phase 
response in randomly selected healthy middle-aged men, which may contribute to the 
increased cardiovascular risk caused by air pollution (Peters A. et al, 2001). 
It has been hypothesized that altered autonomic function and pulmonary/systemic 
inflammation may play a role in the pathophysiologic mechanisms of the PM-health effects. 
Some studies explored the effects of air pollution on autonomic function measured by both 
electrocardiographic monitoring and blood tests. In a US study, 88 elderly subjects were 
involved in multiple sessions of 24-hr ambulatory electrocardiographic monitoring and blood 
tests. Regression analysis was used to evaluate associations between fine particulate matter 
(PM2.5) and HRV, C-reactive protein (CRP), blood cell counts, and whole blood viscosity. 
There was found that the PM2.5–HRV associations were reasonably consistent and statistically 
robust, while associations between CPR and PM2.5 were small but statistically significant 
(Pope A et al, 2004b). 
In North Carolina, US, nine highway patrol troopers (male age 23 to 30) were monitored on 
four successive days while working a three pm. to midnight shift. Each patrol car was 
equipped with air-quality monitors for PM2.5. Blood was drawn 14 hours after each shift, and 
ambulatory monitors recorded the electrocardiogram throughout the shift and until the next 
morning. In-vehicle PM2.5 (average of 24 μg/m3) was associated with decreased lymphocytes 
(11% per 10 μg/m3) and increased red blood cell indices (1% mean corpuscular volume), 
neutrophils (6%), C-reactive protein (32%), von Willebrand factor (12%), next-morning heart 
beat cycle length (6%), next-morning heart rate variability parameters, and ectopic beats 
throughout the recording (20%). Although, controlling for potential confounders had little 
impact on the effect estimates, the observations in these healthy young men suggest that in-
vehicle exposure to PM2.5 may cause pathophysiologic changes that involve inflammation, 
coagulation, and cardiac rhythm (Riediker M. et al, 2004). 
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1.4 MECHANISMS OF PM-RELATED ADVERSE HEALTH EFFECTS 
 
A number of experiments have demonstrated very rapid effects of PM which argues for the 
existence of pathways that convey signals systemically within hours of PM inhalation. On the 
other hand, there is also support for chronic effects, such as the promotion of atherosclerosis.  
The presumed biological mechanisms linking PM air pollution to heart and respiratory 
diseases involve direct effects of PM on the cardiovascular system, blood, and lung receptors, 
and/or indirect effects mediated through pulmonary oxidative stress agents, such as gases, 
ultrafine particles along with soluble constituents of PM2.5 (eg, transition metals), that readily 
cross the pulmonary epithelium into the circulation. In addition, activation of pulmonary 
neural reflexes secondary to PM interactions with lung receptors may play a role. The 
alterations in autonomic tone, under appropriate circumstances, might contribute to the 
instability of a vascular plaque or initiate cardiac arrhythmias. These direct effects of air 
pollution represent a plausible explanation for the occurrence of rapid (within a few hours) 
cardiovascular responses, such as increased myocardial infarctions. Less acute (several hours 
to days) and chronic indirect effects may occur via pulmonary oxidative stress/inflammation 
induced by inhaled pollutants. Subsequently, this may contribute to a systemic inflammatory 
state, which may in turn be capable of activating haemostatic pathways, impairing vascular 
function, and accelerating atherosclerosis.  
The studies support the idea that inhalation of PM can instigate extra-pulmonary effects by 
three general pathways (Figure 5) (Brook RD et al 2010):  
1. the release of pro-inflammatory mediators (eg. cytokines, activated immune cells, 
platelets) or vasculoactive molecules (eg. ET, histamine, microparticles) from lung-
based cells; 
2. perturbation of the systemic autonomic balance or heart rhythm by particle interactions 
with lung receptors or nerves; 
3. potentially traslocation of PM (UFPs) or particle constituents (organic compounds, 
metals) into the systemic circulation. 
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Figure 5 Biological pathways linking PM exposure with CVDs. (A question mark (?) indicates the 
pathway/mechanism with a weak or mixed evidence or a mechanism of likely yet primarily theoretical 
existence based on the literature) 
 
 
The molecular events triggering pulmonary oxidative stress and inflammation, along with the 
interactions between lung, immune cells and the inhaled PM are highly complex. Size, charge, 
solubility, aggregation, ROS-producing potential and chemistry of the particles play roles in 
the determining the responses. These include the particle fate (eg. lung clearance versus 
retention rates), the nature of the PM-cell interactions (eg. immune versus lung cell uptake, 
host cell responses, and intracellular sequestration/location), and the dose (likely typically a 
small percentage of inhaled PM) and pathways of potential systemic transmission of PM or its 
constituents, such as in the circulation (free, intracellular  within circulating cells, 
(lipo)protein-bound) or via lymphatic spread. Because of their nano-scale size, UFPs may 
directly enter multiple lung cell types via nonphagocytic pathways and adversely affect 
organelles, such as mitochondria  (Møller P et al. 2010). Larger unopsonized fine particles are 
more typically taken up by phagocytes through interactions with innate immunity receptors 
(Møller P et al. 2010). Certain particle compounds may directly generate ROS in vivo because 
of their surface chemistry (eg, metals, organic compounds, and semiquinones) or after 
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bioactivation by cytochrome P450 systems (eg, polycyclic aromatic  hydrocarbon conversion 
to quinones) (Møller P. et al. 2010). 
ROS in the lungs has been shown to augment the signal transduction of membrane ligand (eg, 
epidermal growth factor by disrupting phosphatases) or pattern recognition receptors (eg, toll-
like receptors [TLR]) (Hollingsworth JW et al. 2004; Becker S. et al. 2005) and/or stimulate 
intracellular pathways (eg, mitogen-activated protein kinases) that lead to the activation of 
proinflammatory transcription factors (eg, nuclear factor-κβ), that upregulates expression of a 
variety of cytokines and chemokines. Alteration in lung cell redox status may itself stimulate 
nuclear factor-κβ (Figure 6). Biological components within coarse PM could also directly 
trigger inflammation (eg, nuclear factor-κβ pathways) by binding to TLR2 or TLR4 receptors 
or other innate immune pattern-recognition receptors (Becker S. et al. 2005).  
The transcription factor NF-kB induces the expression of genes for: 
 cytokines: TNF-α, IL-1β, IL-6, IL-11, GM-CSF (granulocytes macrophage colony-
stimulating factor); 
 chemotactic factors: IL-8, RANTES (Regulates upon Activation T-cell Expressed and 
Secreted); 
 adhesion proteins: ICAM-1 (Intracellular Adhesion Molecule-1), VCAM-1 (Vascular 
Cell Adhesion Molecule-1) E-selectin; 
 enzymes: iNOS (inducible nitric oxidase synthase), COX-2 (cycloxigenase-2), cPLA2 
(citosolic phospholipase-2) 5-LO (5-lipoxigenase); 
 receptor for: α-chain of the receptor for IL-2, β-chain of the receptor for T-cells. 
Figure 6  Hypothetical sequence of events leading from the contact of particles with the cells (composite 
macrophage/epithelia cell) surface to inflammation (MacNee W., Donaldon K. , 2003) 
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Thus, the release of TNF-α and IL-1 can activate NF-kB, creating a mechanism of positive 
self-regulation for the expansion of the inflammatory response. So the activation of NF-kB 
system can be seen to be highly pro-inflammatory (Jimenez LA. et al. 2000). 
Both macrophages and epithelial cells respond to PM exposure with increase release of 
cytokines. Deposition of PM into alveolar spaces in the lungs may trigger the release of 
cytokines from alveolar macrophages, which may stimulate the epithelial cells to produce 
specific mediators, further enhancing the inflammatory response. In vitro studies show that 
macrophages release TNF when exposed to PM; upon binding to its receptors subtype (TNF-
R55 and TNF-R77), TNF evokes a complicated array of intracellular signals ranging from 
adaptation and protection of oxidative insult to cytotoxicity in the form of apoptosis or 
necrosis. In lung epithelial cells, exposure to TNF cause an increase the secretion of IL-8 
(Flecha B. 2004).  
Increased concentrations of IL-6 are associated with an increased risk of cardiovascular events 
(Ridker PM. et al. 2000; Lindmark E. et al. 2001) and mortality (Volpato S. et al. 2001). 
Serum IL-6, IL-1β, and granulocyte macrophage colony stimulating factor are increased in 
healthy male subjects after exposures to increased air pollution due to forest fires and are 
increased in vitro with exposure of human lung macrophages to urban PM10 (van Eden S. et al. 
2001). IL-6 is directly involved in regulation of the synthesis of C-reactive protein in the liver. 
CRP concentration has been shown to be positively associated with exposure to total 
suspended particles and PM10 (Seaton A. et al. 1999; Peters A. et al. 2001).  
Moreover, although the dominant source of cytokines likely represents the alveolar 
macrophages and lung epithelial cells, the role of other innate and adaptive immune cells 
cannot be ruled out (Fujii T et al. 2002; Hollingsworth JW et al. 2004). Available studies 
support important contributions to pulmonary inflammation from innate immune cells such as 
neutrophils and macrophages (TNF-α, IL-6), as well as from the adaptive immune system, 
such as T cells (IL-1, IL-4, IL-6, and IL-10). This large number of inflammatory mediators 
released from the lung cells after contact with PM could spill over to the general circulation or 
could induce a increase production of acute phase proteins ( eg. C reactive protein, fibrinogen) 
from the liver. Stimulation of the liver that responds with the production and the release of 
acute phase proteins is an early and integral part of the systemic inflammatory response. 
Recent studies have suggested that C-reactive protein (CRP) is an important and independent 
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predictor of cardiovascular disease (Albert et al. 2002). Peters et al. (2001) showed that 
exposure to current ambient levels of particulate matter in the atmosphere elicited an acute 
phase response (e.g. CRP increase) in randomly selected healthy middle-aged men. This was 
further supported by data showing that plasma CRP levels were positively associated with 
higher levels of PM10 (Seaton et al., 1999). PM10 and ultrafine carbon black exposure 
enhance the expression of CRP in human lung epithelial cells, and the increased CRP is able 
to increase the infiltration of monocytes into arterial wall hence leading to atherogenesis by 
amplifying inflammatory and pro-coagulant response (Yeh ET. et al. 2001; Willerson JT. et al. 
2002). 
An integral component of the systemic inflammatory response is the stimulation of the 
hematopoietic system, specifically the bone marrow, which results in an increase in circulation 
leukocytes. The leukocytosis is the result of the accelerated release of PMN, band cells and 
monocytes. Military recruits exposed to high levels of PM10 during the forest fire in Southeast 
Asia in 1997, developed a leukocytosis that was associated with bone marrow stimulation 
(Tan WC. et al. 2000). Two separated studies on healthy subjects that resided in region with 
low PM10 (i.e. the South Pole) for prolonged periods, showed that circulating white blood cell 
count fell below the normal range shortly after the subjects entered this environment, remained 
low for the entire period, and than returned to normal levels once went back in the US 
(Mazzera DM. et al. 2001) and Japan (Sakai M. et al. 2004). 
Emigration of inflammatory cells from blood to tissue site involves up regulation of adhesion 
molecules on vascular endothelium (E-selectin, P-selectin, intercellular adhesion molecule-
1(ICAM-1), vascular cell adhesion molecule-1(VCAM-1) and on circulating leukocytes (L-
selectin, lymphocyte function associated antigen-1, ICAM-1) (Frampton MW. 2001). 
Increased levels of CRP following exposure to particles may play a role in the impairment of 
endothelial function by attenuating NO reactivity and up-regulating expression of ICAM-1, 
VCAM-1 and E-selectin (Peters A. et al. 2001). Mills and colleagues have demonstrated that 
inhalation of diesel exhaust impairs vasomotor response to endothelium dependent and -
independent vasodilators at 6 hours and endogenous fibrinolysis (Mills N. et al. 2005). 
Although the biological pathways responsible for PM-induced endothelial dysfunction have 
not yet been elucidated, an abnormal balance between the release of endothelium-derived 
constricting (ET-1) and relaxing (NO) substances has been proposed. Endothelial dysfunction 
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could significantly contribute to the development of atherosclerosis, acute coronary syndromes 
and MI associated with PM.  
Human AM exposed to PM10 produce IL-1β and TNF-α that up-regulate the secretion of 
monocyte chemoattractant protein-1 (MCP-1) and promote the accumulation of monocytes 
and T lymphocytes in atherosclerotic lesions, hence accelerating the progression of 
atherosclerosis into an advanced stage (van Eeden S. et al. 2001).  
A schematic summary of the events that could lead to cardiovascular events is presented in 
Figure 7. Seaton A. and collaborators proposed in 1995 (Seaton A. et al. 1995) a general 
hypothesis that exposure to inhaled particles induced alveolar inflammation, leading to 
exacerbation of pre-existing lung disease, increased blood coagulability, and associated risk of 
cardiovascular events. Some years later, Peters and collaborators (Peters A. et al. 1997) have 
investigated plasma viscosity, which is determined largely by plasma fibrinogen 
concentration, in a population in relation to a severe air pollution episode (MONICA study, 
Augsburg). They have found an increase on plasma viscosity during the pollution episode.  
An experiment in rats have shown an increase in factor VII following a exposure to ultrafine 
particles. Increased in any proteins of clotting cascade present an increased possibility of 
coagulation. In addition, raised concentrations of fibrinogen and factor VII are recognized 
long-term risk factors for myocardial infarction. 
 
Figure 7. Assumed pathways of inflammatory response elicide by PM (Bai et al. 2007) 
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Several others studies have evaluated the effects of PM exposure on haemostatic markers, 
such as fibrinogen, platelets count, D-dimer, von Willebrand factor. Some of those have not 
observed changes after PM exposure others reported increases coagulatory parameters. 
Ruckerl and colleagues have observed an increase of C- reactive protein (CRP), vWF, 
prothrombin 1+2 but not fibrinogen, d-dimer, FVII after in association with air ambient 
particles (PM10 and PM2.5) (Ruckerl R. et al. 2006). Mills and colleagues have demonstrated 
a significant effect of diesel exhaust on fibrinolytic function in response to intermittent 
exercise both in healthy men and in men with coronary artery disease (Mills N. et al. 2005). 
Rudez and colleagues have demonstrated that PM10 is associated with a increased platelets 
aggregation as well as coagulation activity but had not clear effects on CRP (Rudez G. et al. 
2009). Carlsten and colleagues, in a ranodmized controlled crossover study, have recorded no 
effects on d-dimer, vWF, CRP, platelets count after PM exposure (Carlsten. C. et al. 2007).  
The results related to to thrombosis/coagulation are quite variable given the differences in 
study designs, patients, biomarkers evaluated, and pollutants; however, these adverse effects 
appear somewhat more consistent among higher-risk individuals.  
Mortality associated with air pollution might be further explained, at least in part, by 
alterations in the autonomic input to the heart. Decreased heart rate variability (HRV) predicts 
an increased risk of cardiovascular morbidity and mortality in the elderly and those with 
significant heart disease (Task Force of the European Society of Cardiology and the North 
American Society of Pacing and Electrophysiology, 1996). Because overall HRV decreases in 
response to ambient PM exposure (Pope CA et al. 1999; Liao D. et al. 1999) decreased 
parasympathetic input to the heart may provide an important mechanistic link between air 
pollution and cardiovascular mortality by promoting fatal tachyarrhythmias.  
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2 AIM OF THE PHD PROJECT 
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My PhD project forming a part of the PM-CARE study, a more comprehensive investigation 
designed to examine the mechanisms through which urban air particle exposures worsen 
cardiovascular and respiratory diseases. 
Specific objectives of the PM-CARE study were: 
 identify the pathogenetic mechanisms of the cardiac and respiratory injury induced by 
urban PM; 
 define the role in this process of exposure levels and the single components of urban 
PM; 
 define the deterministic and probabilistic PM risk models both at individual and 
population level; 
 identify the criteria that physicians can use to identify PM as an environmental risk 
factor in cardio-respiratory patients and establish a relation with worsening of the 
disease in single patient. 
 
My doctoral thesis aims at characterize the effects of PM exposure on inflammatory and 
coagulatory indices in susceptible subjects (with chronic heart disease or chronic respiratory 
disease), focused on the role of the fine and ultrafine particles in determining changes in these 
markers.  
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3 MATERIALS AND METHODS 
 39
 
Individual exposure and health measurements were made under a protocol approved by the 
Ethic Committee of the “Luigi Sacco” University Hospital (Milan, Italy) and the “San 
Gerardo” University Hospital (Monza, Italy), for individuals living in the urban and suburban 
area of Milan, Italy, between July 2005 and July 2006.  
Three groups of subjects were studied: i) subjects suffering from chronic ischemic heart 
disease (Heart group), ii) subjects suffering from asthma or chronic obstructive pulmonary 
disease (COPD) (Lung group) and iii) subjects without diagnosis of the afore mentioned 
diseases (Healthy group).  
Each participant underwent a twenty-four hours protocol, during normal unrestricted out-of-
hospital activity, that included evaluation of exposure and health parameters twice, in the 
warm season (no-heating period, May – October) and in the cold season (heating period, 
November – April). A written informed consent was obtained. 
The monitoring protocol was started by trained physicians and technicians in the morning at 
each participants’ home, and ended the following day at the hospital.  
3.1 STUDIED SUBJECTS 
Studied subjects were recruited from the patients community of two Italian hospitals (“Luigi 
Sacco” University Hospital and “San Gerardo” University Hospital), and grouped according to 
their health status into subjects suffering from chronic ischemic heart disease, subjects 
suffering from asthma or chronic obstructive pulmonary disease (COPD) and subjects without 
diagnosis of the afore mentioned diseases. During an initial ambulatory medical visit a 
questionnaire was administered regarding the subject’s demographics, physiological and 
medical history, current medication use, educational qualification and job position, usual sport 
activities intensity, alcohol consumption, smoking history and second-hand smoke (SHS) 
exposure at home. A 12-lead ECG and lung function tests were performed. A blood sample 
was collected for blood test analysis.  
General exclusion criteria included current smokers (or ex-smokers < 6 months), poor 
glycemic control (sHbA1c > 7%, as defined by the “American Diabetes Association” 
Guidelines (Standard of medical care in diabetes, 2007), severe renal failure (serum creatinine 
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> 2,5 mg/dL), moderate-to-severe anemia (Hb < 10 mg/dL), coagulation disorders (PLT < 
150.000 mg/dL; PT-INR < 0,8 or > 1,2; PTT < 21 or 36''; FG < 200 or > 400 mg/dL), 
electrolytic imbalance (Na+ < 135 or > 145 mEq/L; K+ < 3,4 or > 4,8 mEq/L).  
Subjects in the Heart Group were eligible if they had chronic ischemic heart disease defined 
as 1) diagnosis of coronary artery disease (CAD) by at least one of the following: a) a positive 
coronarography, b) a positive provocative test (male), c) a positive myocardial scintigraphy 
(female); 2) a history of chronic stable angina; 3) a prior percutaneous coronary intervention 
(PTCA) or a prior coronary artery bypass surgery at least 6 months before recruitment; or 4) a 
previous myocardial infarction at least 6 months before recruitment. Specific exclusion criteria 
for this group included unstable angina, angina in CANADIAN class 3a or 4a, acute 
cardiovascular events in the previous 6 months, heart failure in NYHA class III or IV, 
anticoagulation therapy, paced rhythm (both pacemaker and implantable cardioverter 
defibrillator > 5% of R), chronic atrial fibrillation, moderate-to-severe COPD or asthma. 
Subjects in the Lung group were eligible if they had 1) mild-to-severe COPD (as defined by 
GOLD guidelines [Pauwels R.A. et al.,2001a; Pauwels R.A. et al., 2001b]); 2) mild-to-severe 
asthma (as defined by GINA guidelines, Bousquet J., 2000). Specific exclusion criteria for this 
group included a vital capacity less than two liters and chronic ischemic heart disease. 
Subjects in the Healthy Group were eligible if they had 1) normal ECG and no heart disease; 
2) normal lung function tests and no lung disease. Specific exclusion criteria for this group 
included upper airways disease (included nasal and paranasal sinus disease), renal disease, 
allergy, and diabetes mellitus.  
3.2 EXPOSURE ASSESSMENT  
Exposure measurements were performed using individual monitoring instruments. All devices 
were assembled on a mobile monitoring unit (MMU), that was equipped to provide self-
contained and unattended 24-hour monitoring, and that was easily transportable by the 
participants during their displacements (Figure 8). All the probes were placed on the top of the 
MMU, at 90 cm from the ground, allowing an individual exposure monitoring. 
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Figure 8 The Mobile Monitoring Unit (MMU) [size 90x45x31 cm, weight about 25 Kg] 
 
 
The protocol included measurements of ultrafine particles number concentration (UFPs), fine 
particles and coarse particles number concentration, PM0.5, PM1, PM2.5, PM10 mass fractions 
and microclimatic parameters (temperature and relative humidity).  
UFPs number concentration was continuously measured with a Condensation Particle Counter 
(CPC, P-TRAK® Ultrafine Particle Counter, TSI Model 8525) for particles in the size range 
0.02–1 µm in DA. Data were recorded by an internal data-logger and downloaded on computer 
at the end of each 24-hour monitoring period with TrakPro software (Version 3.6.2.0, TSI 
Inc.). 
An Optical Particle Counter (OPC, Lighthouse Handheld 3016 Particle Counter) was selected 
to measure fine (from 0.3 to 2.5 µm)  and coarse (from 2.5 to 10  µm) particles number 
concentration. It measured the number of particles having DA> 0,3 µm, sorted into six 
dimensional classes (0.3-0.5; 0.5-1.0; 1.0-2.5; 2.5-5.0; 5.0-10 µm). 
Twenty four hours time weighted gravimetric measurements of PM were performed with a 
personal cascade impactor sampler (PCIS), with three impaction stages and an after-filter that 
allows the separation and collection of airborne particles in the following aerodynamic particle 
diameter ranges: <0.5, 0.5–1.0, 1.0–2.5 and 2.5–10 μm. The PCIS operates in combination 
with the Leland Legacy Sample Pump (SKC Inc., Cat. No. 100–3000) at a flow rate of 9 
L/min. PTFE membranes with PTFE support were used for collection of PM fractions. 
Membrane filters were weighted according to UNI EN 12341. The filters were weighted 
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according to the  D.M. April 2nd 2002, n. 60 and the European Legislation (EN12341).  The 
filters were stored at 20°c with 50% of humidity for at least 48 hours both prior and after the 
monitoring. 
Temperature and Relative Humidity (RH%) were continuously measured with a miniaturized 
microclimatic probe (Lighthouse Worldwide Sol.).  
The MMU was delivered at each subject’ home during the morning of the monitoring day 
(from 8 to 10 a.m.). Our personnel registered some information about house characteristics 
(presence of chimneys, gas heater or other kinds of heaters, carpets, storey, traffic intensity, 
density and height of the surrounded buildings, quality of the windows casing etc..). Each 
subject filled in a questionnaire recording the activity (walking, flame cooking, relax etc..), 
drugs assumption and symptoms occurring in the day of the monitoring. 
 
3.3 HEALTH MONITORING 
3.3.1  INFLAMMATORY MARKERS 
 
Fasting blood samples were obtained from the antecubital vein without tourniquet at the end of 
each 24-hour monitoring protocol at the hospital, using standardized procedures for  
phlebotomy, and were collected into vacuum tubes.  
Blood samples for inflammatory markers were stored at ambient temperature until 4 hours 
from the collection. 2,5 ml of blood were centrifuged at 2400 rpm for 10’ at room temperature. 
Plasma was distributed into aliquots and stored at -20°C until the analysis.  
TNF-alfa, IL-8, soluble receptor I and II of  TNF-alfa and IL-10 levels were estimated both in 
plasma and in vitro following stimulation with phytohemagglutinin (PHA) or 
lipopolysaccharide (LPS), using a commercially available ELISA kits (Immunotools, 
Germany e R&D, USA). The blood samples (2 ml) for the in vitro stimulation of cytokine 
were diluted 1:10 with RPMI 1640 (Sigma, USA), added with 2 mM of L-glutamine, 0.1 
mg/ml streptomycin and 100 IU/ml penicillin (Sigma), and incubated with 5% CO2 at room 
temperature in polypropylene tubes in presence or not of LPS (1 mcg/ml; Sigma Cat. L3129) 
or PHA (1.2 mcg/ml; Gibco, Cat. 10576-015) during 24 hours for the release of IL-8 e TNF-
alfa and for 72 h for the release of  IL-10. The samples were centrifuged at 1500 rpm for 10 
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minutes at room temperature and the surnatant was distributed into aliquots and stored at -
20°C until the analysis.  
High-sensitivity C reactive protein (hsCRP) serum concentrations were measured using a near 
infrared particle immunoassay method using IMMAGE® Immunochemistry Systems Reagent 
(Beckman Coulter Inc., Fullerton, CA). 
3.3.2 COAGULATION PARAMETERS  
 
Blood samples were collected as previously described (see above). The blood was centrifuged 
at 3000rpm for 20 minutes at 4°C, then plasma was distributed into four aliquots and stored at 
-80°C until the analysis. The measure of D-dimer, von Willebrand factor (vWF), tissue 
plasminogen activator (tPA) and prothrombin fragment F1+2 (F1+2) were performed using 
available commercially ELISA kits.  
The platelet activation was determined using the Dade Behring (Miami, FL) platelet function 
analyzer (PF-100®). Using this instrument, the blood–citrate mixture is aspirated under a 
constant negative pressure and contacts an ADP/epinephrine and collagen-coated membrane. 
The blood then passes through an aperture that induces high shear and simulates primary 
hemostastis after small blood vessel injury under flow conditions. The time to aperture 
occlusion (closure time, PFA 100 C-EPI CT, PFA 100 C-ADP CT) is recorded in seconds and 
is inversely related to the degree of platelet activation (Kundu Sk et al. 1995, Mammen EF et 
al. 1995).  
Fibrinogen, aPTT and INR were measured with standardized methods used in the H. Sacco 
Hospital. 
3.3.3 COMPLETE BLOOD CELLS COUNT 
 
Complete blood count with differential leukocytes analysis were performed using standardized 
method used in the H. Sacco Hospital. 
. 
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3.4 STATISTICAL ANALYSIS 
 
All data were tested for normality with Kolmogorov-Smirnov Test. Data were ln-transformed 
to achieve normality for statistical analysis purpose, when necessary. Parametric test (paired 
Student’s T test) or non parametric test (Wilcoxon test) were used, depending on the 
distribution of data, to assess differences in clinical parameters between the two monitoring 
periods (cold and warm season).  
Since the three groups had different clinical status, each group were analyzed independently 
using mixed effects models for repeated measurements to evaluate the associations between 
particles exposure and clinical parameters. The structure with repeated measures takes into 
account the variable time between the two monitoring period and visits. Model selections were 
based on the criteria of minimizing Akaike’s Information Criterion (Akaike H. 1974).  
The daily average PM exposure was matched with the biological parameters measured at the 
end of the 24 hours monitoring. Models include time varying factor (PM, temperature and 
relative humidity) and time-invariant subjects specific characteristics (age, gender, BMI, drug 
assumption). Pollution effects were expressed as percent changes by interquartile range (IQR) 
changes as [e (β*IQR)-1]*100 for ln-transformed data and [β*IQR/Media]*100 for parametric 
data, where β and M are the estimated regression coefficient and the mean of each blood 
marker, respectively (Chuang K. et al. 2007).  
Statistical computations were performed with SPSS software version 18.  
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4 RESULTS 
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4.1 STUDIED SUBJECTS 
 
Out of the 112 volunteers contacted at the beginning of the study, 98 resulted eligible 
according to the established inclusion criteria of the study but, successively, 5 subjects 
dropped out for clinic reasons and 12 for scarce compliance. Then, the total group of 
volunteers enrolled for the 24h-monitoring was composed by 81 individuals: 34 suffering from 
chronic ischemic heart disease (Heart Group), 20 from chronic obstructive pulmonary disease 
or asthma (Lung Group) and 27 were characterized by absence of before mentioned heart or 
lung pathologies (Healthy Group).  
The mean age for the overall studied population was 64±10 years at the beginning of the study 
and the gender was male for the 63% of individuals. Considering groups, the mean age and the 
male gender were respectively 61±7 years and 48% within the Healthy group, 66±10 years 
and 82% within the Heart group and 65±11 years and 50% within the Lung Group.  
Subjects were generally overweight in all groups. Current smokers were not included in the 
study, although about half of them were former smokers (56%). Diabetes mellitus is totally 
absent in Healthy Group, while 24% and 15% out of individuals in the Heart and in the Lung 
Group, respectively, suffered from diabetes mellitus. In the total group 51% out of individuals 
suffered from hypertension, corresponding to the 26%, 71%, 50% in the Healthy, in the Heart 
and in the Lung Group respectively. In the Heart Group the majority of subjects underwent a 
PTCA or coronary artery bypass surgery (79%) or had a history of myocardial infarction 
(68%). Out of the Lung Group, 56% suffered from chronic obstructive pulmonary disease 
(COPD), 56% from asthma. Medications use differed in the three groups, depending on health 
status. General characteristics, as anthropometric description, physiological and medical 
history, drug assumption of studied population, are resumed in Table 1. 
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Table 1 Demographic characteristics, physiological and medical history, drug assumption of studied 
individuals (total sample and three groups). [Data are shown as mean±SD or as n (%)]. 
   Total Group Healthy Group Heart Group Lung Group 
  n (%) n (%) n (%) n (%) 
Subjects 81 27 34 20 
          
Age (mean±SD) 64±10 61±7 66±10 65±11 
BMI (mean±SD) 27±5 26±4 26±4 29±6 
Male gender 51 (63%) 13 (48%) 28 (82%) 10 (50%) 
          
Alcohol assumptiona 39 (48%) 16 (59%) 16 (47%) 7 (35%) 
Physical activityb 35 (43%) 23 (85%) 7 (21%) 5 (25%) 
Former smoker 45 (56%) 13 (48%) 22 (65%) 10 (50%) 
          
Hypertension 41 (51%) 7 (26%) 24 (71%) 10 (50%) 
Dyslipidemia 39 (48%) 14 (52%) 18 (53%) 7 (35%) 
Diabetes mellitus 11 (14%) 0 (0%) 8 (24%) 3 (15%) 
          
ACE-inhibitor 27 (33%) 3 (11%) 20 (59%) 4 (20%) 
β-blockers 29 (36%) 1 (4%) 27 (79%) 2 (10%) 
Calcium channel antagonist 11 (14%) 1 (4%) 6 (18%) 4 (20%) 
Diuretic drugs 22 (27%) 3 (11%) 15 (44%) 5 (25%) 
Other anthypertensive treatment 40 (49%) 5 (19%) 27 (79%) 9 (45%) 
Statins  29 (36%) 1 (4%) 26 (76%) 2 (10%) 
Aspirin (anticlotting) 34 (42%) 2 (7%) 31 (92%) 1 (5%) 
Anticoagulants 6 (7%) - 6 (18%) - 
Long acting β2-agonist 11 (14%) 0 (0%) 0 (0%) 11 (55%) 
Inhaled corticosteroids 9 (11%) 1(4%) - 8(40%) 
Hypoglycemic Agents 10 (12%) - 7 (21%) 3 (15%) 
NSAIDs 4 (5%) - 1 (3%) 1 (5%) 
Vitamins 6 (7%) 3 (11%) 0 (0%) 3 (15%) 
Notes: a Alcohol assumption more than two glasses per day; b Physical  activity from moderate to intense.  
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4.2 EXPOSURE DATA 
 
The median (25°-75° percentiles) 24h concentration of PM10 during the no-heating period was 
35.5 (29.3-51.1) μg/m3 and during the heating period  58.0 (41.7-79.0) μg/m3. For PM2.5, the 
median (25°-75° percentiles) concentration during the no-heating period was 26.8 (21.4-37.7) 
μg/m3 and during the heating period  49.8 (33.7-66.3) μg/m3. The mean temperature was 25.3 
(23.0-28.5)°C and the relative humidity was 37.4 (33.5-43.3) (Table 2).  
Comparing the data from the two monitoring periods, the results showed a significant increase 
for particulate matter concentrations in the heating ignition power-on period (Wilcoxon test, 
p<0.05). The PM10 percentage variation was 63.4% and for PM2.5 was 85.8 % (Table 2). 
Table 2 Air particulate pollutants levels (median [25°-75°]) of the two 24h-monitoring set during both the 
period with heating ignition power-on and power-off for the whole sample of volunteers involved in the 
study. Percentage variation of medians level between the two set of 24-h-monitorings and relative 
difference significance are also reported (Wilcoxon test, * p<0.05). 
 
No heating Heating No H vs H 
Median Median   
Environmental 
parameters         
[24 h TWA (µg/m3)] 25° 75° 25° 75° Δ% Wilcoxon test 
19.74 38.70 PM0,5 
15.37 28.12 24.53 52.41 
96.5 * 
22.72 43.72 PM1 
17.81 31.78 28.67 58.72 
92.5 * 
26.79 49.81 PM2,5 
21.38 37.67 33.65 66.25 
85.8 * 
35.54 58.04 PM10 
29.27 50.98 41.73 79.02 
63.4 * 
28.5 23.1 T °C 
26.9 30.3 27.5 23.1 
- 20 * 
42.5 34.3 Relative Humidity 
37.9 45.0 31.6 37.3 
- 20 * 
 
 
No heating Heating No H vs H 
Median Median   
Environmental 
parameters              
[ 24h mean (#/cm3)] 25° 75° 25° 75° Δ% Wilcoxon test 
16969 24958 UFP 0.02-1 µm  
13526 22082 17290 34025 
32 * 
73.100 172.900 FP 0.3-0.5 µm  
41.100 101.100 102.100 249.300 
58 * 
4.700 15.400 FP 0.5-1 µm  
3.100 9.000 9.300 25.100 
69 * 
0,388 0,764 FP 1-2.5 µm  
0.238 0.550 0.563 1.099 
49 * 
0.177 0.233 CP 2.5-5 µm  
0.131 0.275 0.163 0.369 
24 * 
0.015 0.018 CP 5-10 µm  
0.010 0.093 0.092 0.138 
17 * 
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The three groups of subjects were exposed to similar PM concentration, except for fine 
particles (PM0.5, FP0.3-1 D.a), that were higher in the Healthy group (Table 3).  
 
Table 3 Air particulate pollutants levels (median [25°-75°]) in total population, in each studied group and 
differences among groups (RA: ANOVA for repeated mesurements, * p<0.05) 
Environmental 
parameters  
Total 
Population 
  Healthy Heart Lung 
Heating+ 
No Heating 
Median         
25°-75° 
RA 
Median          
25°-75° 
Median        
25°-75° 
Median         
25°-75° 
27.1 31.3 28.1 20.6 
PM 0.5 
17.8-42.4 
*  
19.8-50.3 18.1-37.1 15.3-41.7 
31.1 35.5 31.4 23.5 
PM 1 
20.5-46.7 
  
23.0-53.3 20.1-40.3 17.8-46.8 
35.2 40.0 35.7 29.0 
PM 2.5 
24.6-50.7 
  
27.2-57.9 25.2-46.1 20.7-50.4 
45.7 50.3 48.3 38.5 
PM 10 
32.5-63.0 
  
35.4-69.7 34.8-59.8 27.5-60.1 
19443 19441 19545 19084 
UFP 0.02-1 
14520-30328 
  
15269-28912 13898-30739 14139-30515 
101.2 149.2  100.8  63.8 FP 0.3-0.5 
 58.0-184.8 
* 
74.9-223.5  67.8–156.9  42.3-175.3 
9.1 13.2  8.9  5.1 FP 0.5-1.0 
 4.2-17.3 
 * 
5.6 – 20.3  4.7 -12.8   3.0- 19.3 
0.552 0.526  0.595  0.444 FP 1.0-2.5 
 0.335-0.871 
  
0.357-0.915 0.382- 0.875 0.263-0.808 
0.203 0.220 0.205  0.192 CP 2.5-5.0 
 0.147-0.326 
  
0.155- 0.305 0.142- 0.351 0.138- 0.294 
0.017 0.019  0.014  0.015 CP 5.0-10 
 0.009-0.118 
  
0.012- 0.130 0.009- 0.103 0.008- 0.121 
25.3 25.3 25.2 25.4 
Temperature 
23.0-28.5 
  
23.1-28.5 22.7-28.9 23.1-28.3 
37.4 39.7 38.2 34.6 Relative 
Humidity 33.5-43.3 
* 
34.1-44.2 34.3-43.7 31.6-40.4 
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4.3 ASSOCIATION BETWEEN CLINICAL AND EXPOSURE DATA 
 
Descriptive data for the haematological parameters are shown in Table 4, Table 5 and Table 6 
(the last in the Appendix). All the parameters of complete blood cells count, coagulatory 
parameters and C reactive protein were in the normal range value given by the laboratory 
where the analysis were done. Reliable reference value are generally lacking for cytokines. 
The subjects in the three groups provided different values of total leukocytes count, 
inflammatory parameters and coagulation parameters (Table 4, Table5). Healthy group 
showed lower values of leucocytes, neutrophils, monocytes and eosinophils than those in 
Heart and Lung groups. As regard to inflammatory parameters, Healthy group displayed 
lower values of sRII-TNF-alfa than Heart group, and Lung group showed lower values of IL-
10 (after stimulation with PHA) than those in Heart and Healthy groups. Concerning 
coagulation parameters, Heart group presented longer closure time (PFA-100 C-EPI CT) than 
Lung and Healthy groups, and Healthy group showed lower values of d-dimer than those in 
other two groups.  
A preliminary analysis of heating and no-heating period results showed a spread distribution 
inflammatory parameters during the heating period (Table 6, Appendix). A comparison 
between heating and no-heating data showed significantly higher heating values in the three 
separated groups. The Heart group showed increased values of erythrocytes, haematocrit, 
leukocytes, monocytes, sRII-TNF-alfa, TNF-alfa and IL-8 (both after stimulation with LPS), 
d-dimer, while the Lung group showed IL-8 increased. The Healthy group showed  increased 
values of erythrocytes, platelets, sRII-TNF-alfa, IL-8 (after stimulation with LPS), d-dimer 
and a shorter closure time (PFA-100 C-EPI CT). 
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Table 4 Descriptive statistic and differences between groups of hematological parameters in total 
population, Healthy, Heart and Lung group. (results expressed as median, 25°-75° percentiles; RA: 
ANOVA for repeated measurements, * p<0.05) 
 Total sample RA “Healthy” group Heart group Lung group 
Subjects [n] 81  27 34 20 
 
Median 
25°-75° 
 
Median 
25°-75° 
Median 
25°-75° 
Median 
25°-75° 
Eritrocytes [106/μL] 
4.7 
4.41-5.06 
 
4.66 
4.33-5.12 
4.6 
4.38-4.90 
4.83 
4.54-5.07 
Platelets [103/μL] 
225 
187-268 
* 
246 
212-278 
209 
174-229 
253 
188-295 
Haemoglobin [g/dL] 
14.3 
13.27-15.30 
 
14.25 
13.20-15.42 
14.35 
13.3-15.2 
14.3 
13.2-15.13 
Haematocrit [%] 
42.55 
39.68-45.30 
 
42.15 
39.43-45.73 
42.3 
39.58-44.92 
43.5 
40.28-45.25 
Leukocytes [103/μL] 
6.41 
5.51-7.28 
* 
5.77 
5.03-6.91 
6.56 
5.85-7.37 
6.54 
5.93-8.19 
Neutrophils [103/μL] 
3.55 
2.91-4.40 
* 
3.01 
2.61-3.86 
3.80 
3.17-4.52 
3.83 
3.02-4.76 
Lymphocytes [103/μL] 
1.99 
1.62-2.36 
 
1.99 
1.65-2.27 
1.93 
1.48-2.45 
2.04 
1.70-2.41 
Monocytes [103/μL] 
0.46 
0.38-0.58 
* 
0.40 
0.35-0.50 
0.52 
0.40-0.60 
0.49 
0.41-0.63 
Eosinophils [103/μL] 
0.16 
0.10-0.28 
* 
0.12 
0.09-0.18 
0.15 
0.07-0.28 
0.23 
0.16-0.31 
Basophils [103/μL] 
0.03 
0.02-0.03 
 
0.02 
0.02-0.03 
0.03 
0.02-0.04 
0.03 
0.02-0.04 
      
sRI-TNFα [pg/mL] 
402 
308-557 
 
422 
317-554 
440 
311-593 
356 
296-483 
sRIITNFα [pg/mL] 
916 
400-1993 
* 
428 
360-1648 
1457 
405-2058 
854 
403-2013 
TNFα [pg/mL]a 
689 
351.25-1132.25 
 580 
320-895 
778 
368-1270 
724 
395-894 
IL8 [pg/mL]a 
7113 
4350-14355 
 
6800 
4363-10963 
6680 
4057-14400 
9200 
4500-18870 
IL10 [pg/mL]b 
25.0 
7.0-59.0 
* 
24.0 
12.0-60.0 
36.0 
7.0-91.5 
8.0 
0.5-33.5 
Hs PCR [mg/L] 
0.69 
0.39-1.50 
 
0.59 
0.55-1.37 
0.44 
0.51-1.28 
1.34 
0.53-1.77 
a  in vitro following stimulation with LPS; b in vitro following stimulation with PHA 
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Table 5 Descriptive statistic and differences between groups of hematological parameters in total 
population, Healthy, Heart and Lung group. (results expressed as median, 25°-75° percentiles; RA: 
randomized one way ANOVA, * p<0.05) 
 Total sample RA “Healthy” group Heart group Lung group 
Subjects [n] 81  27 34 20 
 
Median 
25°-75° 
 
Median 
25°-75° 
Median 
25°-75° 
Median 
25°-75° 
D-dimer [ng/mL] 
169 
111-299 
 
* 
131 
80-203 
224 
136-393 
166 
123-239 
PFA-100 C-EPI CT [s] 
135 
111-263 
* 
121 
111-149 
278 
130-301 
120 
105-152 
PFA-100 C-ADP CT [s] 
83 
73-97 
 
87 
77-96 
82 
69-100 
84 
73-98 
vWF [%] 
119 
85-159 
 
112 
82-142 
132 
94-197 
114 
79-138 
F1+ 2 [pmol/L] 
137 
111-171 
 
138 
113-161 
134 
109-172 
140 
111-194 
tPA [ng/mL] 
6 
4-8 
 
6 
4-8 
6 
5-9 
6 
4-8 
Fibrinogen [mg/dL] 
404 
357-481 
* 
394 
342-448 
398 
359-492 
469 
393-515 
INR 
1.10 
1.00-1.10 
* 
1.00 
0.98-1.10 
1.10 
1.00-1.11 
1.10 
1.00-1.10 
aPTT [s] 
30.05 
28.00-32.58 
 
29.40 
27.37-31.98 
30.90 
28.00-33.10 
30.70 
28.90-32.70 
 
 
 
Association between hematological parameters and PM  
 
Total blood cells count 
The results of the mixed models showed significant changes in monocytes number in the 
Heart group associated with PM0,5, PM1, PM2,5, PM10 (Table 7 Appendix). The monocytes 
increased of 7.90 % (p=0.06) in association with PM10 (Figure 9).  
Variations in lymphocytes number in Healthy group were associated with a large number of 
PM fraction (PM0,5, PM1, PM2,5, PM10, UFP, FP0,3-1) (Table 8, Appendix). The lymphocytes 
increased of 8,71 % (p=0,01) in association with PM10 (Figure 11). 
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Figure 9. Percentage changes in monocytes number for an interquartile range change of PM10 
The values are presented as percentage changes and 95% confidence intervals for interquartile range 
changes after adjusting for sex, age, body mass index, statins, FANS, temperature and relative humidity. 
 
 
 
 
 
 
 
Figure 10 Percentage changes in monocytes number for an interquartile range change of FP0.3-0.5 
The values are presented as percentage changes and 95% confidence intervals for interquartile range 
changes after adjusting for sex, age, body mass index, statins, FANS, temperature and relative humidity. 
 
 
 
 
 
 
 
In the Lung group there is a negative association with monocytes and lymphocytes with PM0,5, 
PM1, PM2,5, PM10, FP0,3-2,5 and FP0,3-2,5 respectively (Table 7, Table 8 Appendix). The number 
of monocytes decreased of 14.73% (p=0,01) in association with PM10 (Figure 9); and 
decreased of 14.45% (p=0.02) in association with FP0.3-0.5 (Figure 10). The lymphocytes 
decreased of 11.48 % (p=0.04) in association with FP0.3-0.5 ( Figure 12). 
Figure 11. Percentage changes in lymphocytes number for an interquartile range change of PM10 
The values are presented as percentage changes and 95% confidence intervals for interquartile range 
changes after adjusting for sex, age, body mass index, statins, FANS, temperature and relative humidity. 
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Figure 12 Percentage changes in lymphocytes number for an interquartile range change of FP0.3-0.5 
The values are presented as percentage changes and 95% confidence intervals for interquartile range 
changes after adjusting for sex, age, body mass index, statins, FANS, temperature and relative humidity.  
 
 
 
 
 
 
 
 
 
Erythrocytes number increased in Heart group of 2.14 % (p=0,02) in association with FP0.3-0.5 
(Figure 13) and of 1,9 % (p=0.01) in association with CP5-10 (Figure 14) (Table 9, Appendix).  
Figure 13 Percentage changes in erythrocytes number for an interquartile range change of FP0.3-0.5 
The values are presented as percentage changes and 95% confidence intervals for interquartile range 
changes after adjusting for sex, age, body mass index, FANS, temperature and relative humidity. 
 
 
 
 
 
 
 
Figure 14 Percentage changes in erythrocytes number for an interquartile range change of CP5-10 
The values are presented as percentage changes and 95% confidence intervals for interquartile range 
changes after adjusting for sex, age, body mass index, FANS, temperature and relative humidity. 
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Platelets number increased in Heart group of 6.77 % (p=0.08) in association with PM0.5 
(Figure 15) and of 5.19 % (p=0.08) with CP5-10  (Figure 16 ), although the relation is slight 
significant (Table 10, Appendix). 
Figure 15 Percentage changes in platelets number for an interquartile range change PM0.5. 
The values are presented as percentage changes and 95% confidence intervals for interquartile range 
changes after adjusting for sex, age, body mass index, anticlotting therapy, temperature and relative 
humidity. 
 
 
 
 
 
 
 
 
 
Figure 16 Percentage changes in platelets number for an interquartile range change CP5-10. 
The values are presented as percentage changes and 95% confidence intervals for interquartile range 
changes after adjusting for sex, age, body mass index, anticlotting therapy, temperature and relative 
humidity. 
 
 
 
 
 
 
 
 
No statistical associations were found for other parameters.  
 
Inflammatory parameters 
No statistical associations were found for cytokines, interleukins and C reactive protein.  
 
Coagulatory parameters 
Among the coagulatory parameters there were negative associations between closure time 
(estimated with PFA-100 C-EPI) and PM0,5, PM1, PM2,5, FP0,3-1, CP2.5-10 in Healthy group, and 
with PM0,5, PM1, PM2,5, PM10, FP0,3-2.5, CP2.5-5 in Heart group (Table 11, Appendix). The 
healthy
heart
lung 
-10
-5
0
5
10
15
Groups
%
 ch
an
ge
 o
f p
la
te
let
s n
um
be
r 
pe
r 
IQ
R
 o
f P
M
 0
,5
healthy lung 
heart
-10
-5
0
5
10
15
Groups
%
 c
ha
ng
e 
pl
at
el
et
s 
nu
m
be
r 
pe
r 
IQ
R
 C
P 
5-
10
 56
closure time was shortened of 10 % (p=0.06) in association with PM1 and of 6.81 % (p=0.05) 
with FP0,5-1 in Healthy group (Figure 17, Figure 18). In Heart group closure time was 
shortened of 17.84 % (p=0.02) in association with PM1 and of 14.98 % (p=0.004) with FP0,5-1 
(Figure 17, Figure 18).  
No changes were present in the Lung Group.  
Figure 17 Percentage changes in closure time for an interquartile range change of PM1 
The values are presented as percentage changes and 95% confidence intervals for interquartile range 
changes after adjusting for sex, age, body mass index, anti-clotting therapy, temperature and relative 
humidity. 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 Percentage changes in closure time for an interquartile range change of FP0.5-1 
The values are presented as percentage changes and 95% confidence intervals for interquartile range 
changes after adjusting for sex, age, body mass index, anti-clotting therapy, temperature and relative 
humidity. 
 
 
 
 
 
 
 
 
 
 
In Healthy group the tissue type plasminogen activator is positive associated with PM0,5, PM1, 
PM2,5, PM10, UFP0.02-1, FP0,3-0,5 FP0,5-1 (Table 12, Appendix). The tPA varied of 22.47% 
(p=0.07) in association with PM1 and of 22.38% (p=0.05) with FP0,3-0,5  (Figure 19, Figure 20).  
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Figure 19 Percentage changes in tPA an interquartile range change of PM1. 
The values are presented as percentage changes and 95% confidence intervals for interquartile range 
changes after adjusting for sex, age, body mass index, anti-clotting therapy, temperature and relative 
humidity. 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 Percentage changes in tPA an interquartile range change of FP0,3-0,5 
The values are presented as percentage changes and 95% confidence intervals for interquartile range 
changes after adjusting for sex, age, body mass index, anti-clotting therapy, temperature and relative 
humidity. 
 
 
 
 
 
 
 
 
No statistical associations were found for other parameters.  
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5 DISCUSSION  
 59
 
Investigated subjects experienced high levels of individual exposure to PM2.5 and PM10. In 
particular, exposure to PM2.5 exceeded the 24-hour mean of 25 µg/m3 suggested by WHO in 
both the investigated periods, i.e. warm and cold season, while the limit suggested for PM10 
(i.e 50 µg/m3) was exceeded only in cold season (WHO, 2005). Observed PM10 concentrations 
were similar to twenty four hours average reported for urban background in Europe (Larssen 
S. et al. 2005), and PM2.5 concentrations were similar to the previously reported for personal 
monitoring indoor and outdoor in Milan (Rotko T. et al. 2002).  Moreover, UFPs levels could 
be considered in the high range, given that number concentration of particles smaller than 100 
nm in urban background environments can range from a few thousand to some 20.000 
particles per cm3 (WHO 2005; Morawska, L et al. 2003). As expected, higher levels of 
exposure to almost all particles were observed in the cold season. The great contribution of 
these higher winter levels is mainly due to particles in the accumulation mode (FP0.3-1 µm). In 
cold season the PM levels are strongly affected not only by the stability of the atmosphere and 
a low degree of air convection (characteristics of the warm season), but also by the heating 
which is one of the major sources of the particles in the accumulation mode. The contribution 
of the higher PM cold season levels of the coarse particles was relatively low because their 
sources are linked to mechanical or natural processes, quite independent from the seasonal 
phenomena.  
The different levels of exposure among the three groups were mainly caused by fine particles 
in the accumulation mode (FP0.3-1 µm) and the Healthy group seemed to be the higher 
exposed. An analysis of the activity of these subjects showed that they have spent more time 
outdoor than the subjects of other groups, so they were much exposed to the particles from 
outdoor origin, the particles in the accumulation mode, confirming the outdoor origin of these 
particles. No differences were recorded for ultrafine particles that in fact have indoor sources 
predominantly. 
A comparative analysis of the biological data among the three groups shows that the Healthy 
group presented strongly different values from the other groups, as expected. The Healthy 
subjects’ data showed a narrow distribution respect to those of the other subjects and the 
median values of the majority of the parameters were generally lower, confirming a great 
status of health of these subjects compared with the others. The Heart group showed an 
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impairment of the coagulation parameters in comparison to the others , probably due to the 
characteristics of the diseases and the assumed anti-clotting therapy. The Lung group seemed 
to have an impairment of the activation of the antinflammatory markers with a persistent low 
grade condition of inflammation, characterised by higher levels of total leukocytes count, an 
increased level of fibrinogen and a reduced release of an anti-inflammatory interleukin, the IL-
10.  
The increase of monocytes, erythrocytes and platelets number in Heart group and 
lymphocytes number in Healthy group in association with fine and coarse particles could 
suggest an increased bone marrow activity, involving a variety of cell types, as a result of the 
effects of cytokines and chemokines from the lung that spill over into the circulation and 
trigger a cascade of inflammatory reactions signals generated in the lung. The leukocytosis  
associated with the activation of bone marrow activity was demonstrated in human exposed to 
PM, that reacted mobilizing leucocytes into circulation as a part of systemic exposure (Tan 
WC. et al. 2000; Sakai M. et al. 2004).  
On the other hand, subjects in Lung group show very little differences between heating and  
no-heating  inflammatory results probably due to a low grade systemic inflammation persistent 
both in no-heating and heating period, which is likely because of the characteristics of the 
pathologies of the subjects belonging this group. Moreover they were exposed to small 
excursion of PM levels that may result in a not appreciable changes in blood measures of 
inflammation and coagulation. We observed a negative association between PM and 
monocytes and lymphocytes number that could be explain by the presence of allergic subjects 
in this group; the summer PM in Milan is more rich in pollens, endotoxins and biological 
materials (Camatini M. et al. 2010) so we could hypothesize a pro-allergic effects of no-
heating PM exposure, an increase of the inflammatory pattern during the no-heating period 
and a slow decrease during the heating period.  
The activation of the platelets aggregation capacity, measured as closure time with PF 100 
Analyzer®, in Heart and Healthy groups in association with fine particles could suggest that 
particles with little aerodynamic diameter could pass directly from the alveoli to the blood and 
interact with the platelets, impairing their aggregability. Another possible mechanism of 
platelets activation might reside in the pulmonary oxidative stress and the activation of subsets 
of white blood cells that lead to a systemic lowering of endothelial- and platelet-derived 
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nitrogen oxide and concomitant platelets activation (Brook RD et al 2008). Moreover, 
although fibrin formation were not confirmed by elevated d-dimer and protrombin fragments 
levels, the increment of the tissue type plasminogen activator in the Healthy group in 
association with fine particles could suggest an increased thrombin generation and a reduced 
fibrinolytic activity; this because the immunoassay of t-PA measures, to a large extend, the 
circulating complex between t-PA and the main fibrinolysis inhibitor plasminogen activator 
inhibitor-1 (Nordenhem A. et al. 1998).  
The lack of consistencies in the association with PM and cytokines and interleukins could be 
explain by their very short half life (2-6 hours). We have measured these factor after about 12 
hours of the higher PM exposure levels, missing probably the concentration peaks in the 
blood. While the lack of consistencies in the association with PM and fibrinogen and C 
reactive protein could be due to the time necessary for the ex-novo synthesis of these proteins 
in the liver, that requires an induction time of 1-2 days (Seaton A. et al. 1999, Ruckerl R. et al. 
2006).  
 
The strength of this study is that it is one of the few using individual monitoring of both 
gravimetric and number concentration of particles with different aerodynamic diameters (from 
ultrafine to coarse particles). The use of fixed site monitoring stations could not be 
representative of personal exposure resulting in imprecise associations (Delfino RJ. et al. 
2008), therefore the individual monitoring is the only way to measure the real exposure in 
particular of our subjects, that were already retired and have spent the greater part of the day 
within their home.  
A limitation of our study is that we enrolled a small number of subjects with different 
pathologies and drug therapies, that had a large impact on the biological parameter. Moreover 
we monitored these subjects only twice, resulting in few data for each subjects.  
Despite of these limitation, this work supports the hypothesis that exposure to PM results in a 
systemic inflammatory response, characterized by stimulation of bone marrow activity, that 
could increase the blood coagulability.  It could also support the hypothesis that small particles 
may translocate form the lung into circulation and directly activate platelets and blood vessels. 
Together these mechanisms may account for the increase of cardiovascular events associated 
with episodes of air pollution. 
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6 CONCLUSION 
 63
 
The results suggest that PM exposure could contribute to the risk of cardiovascular events, in 
particular in elderly and subjects with cardiovascular diseases. The cardiovascular diseases 
representing 29% of the total deaths in 2004, and of these deaths, an estimated 7.2 million 
were due to coronary heart disease and 5.7 million were due to stroke (WHO, Cardiovascular 
disease fact sheet, 2009). Since there are evidences linking PM air pollution exposure and 
cardiovascular mortality and morbidity, may we consider PM as a risk factor for 
cardiovascular diseases or not? Particulate matter exposure is ubiquitous, it may continuously 
enhance acute cardiovascular risk among susceptible people worldwide; moreover it may 
further elicits numerous adverse biological responses that could augment cardiovascular risk 
over the long term. Therefore, PM could surely considered as a factor that modify and 
contribute to cardiovascular mortality and morbidity (Brook RD et al. 2010).  
Despite the huge amount of studies about health effects of PM exposure, some issues remain 
open:  
 to define the role of particles with different aerodynamic diameters and their chemical 
composition; 
 to characterize the contribution of other co-pollutants (ozone, nitrogen dioxide, sulphur 
dioxide); 
 to assess the importance of regional and intracity differences in composition and 
combination of pollutants; 
 To better define the susceptible subjects and define recommendations to help to reduce 
PM exposure; 
 To define whether there is a safe PM threshold concentration that eliminates both acute 
and chronic effects in susceptible subjects but also in general population.   
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Table 6 Differences of blood parameters during the heating and no-heating period in the three groups and differences among groups. Data shown as median 
25th-75th; * for p<0.05; a in vitro after stimulation with LPS;  b in vitro after stimulation with PHA 
 
 Differences between no-heating and heating period  
Dif. among 
groups 
 “Healthy” Group Heart Group Lung Group 
 No-heating Heating  T
e
s
t
 
No-heating Heating  T
e
s
t
 
No-heating Heating  T
e
s
t
 
N
o
-
h
e
a
t
i
n
g
 
h
e
a
t
i
n
g
 
Subjects [n] 27 27  34 34  20 20    
Eritrocytes [106/μL] 
4.58 
4.29-5.07 
4.77 
4.43-5.17 
*
4.58 
4.29-4.88 
4.63 
4.44-5.00 
*
4.86 
4.54-5.06 
4.80 
4.54-5.06 
*   
Platelets [103/μL] 
242 
212-270 
249 
218-290 
*
197 
169-226 
211 
175-229 
 
244 
198-290 
260 
187-309 
 * * 
Haemoglobin [g/dL] 
14.20 
13.10-15.40 
14.30 
13.20-15.50 
 
14.40 
13.15-15.05 
14.25 
13.30-15.32 
*
14.15 
13.20-15.12 
14.30 
13.18-15.20 
   
Haematocrit [%] 
41.80 
39.10-45.20 
42.50 
39.60-46.10 
 
41.80 
39.20-44.50 
43.00 
40.40-45.90 
*
43.60 
40.90-44.50 
43.35 
39.43-45.65 
   
Leukocytes [103/μL] 
5.71 
5.06-6.94 
5.80 
4.97-6.90 
 
6.52 
5.80-7.21 
6.59 
5.97-7.49 
*
6.92 
5.94-8.41 
6.41 
5.73-7.77 
 * * 
Neutrophils [103/μL] 
2.98 
2.57-4.09 
3.01 
2.66-3.84 
 
3.88 
3.12-4.49 
3.76 
3.34-4.87 
 
3.84 
3.12-4.75 
3.67 
2.95-4.90 
 * * 
Lymphocytes [103/μL] 
1.86 
1.53-2.27 
2.04 
1.76-2.29 
 
1.93 
1.48-2.42 
1.92 
1.47-2.51 
 
2.12 
1.72-2.39 
1.98 
1.67-2.42 
   
Monocytes [103/μL] 
0.37 
0.33-0.51 
0.42 
0.38-0.50 
 
0.49 
0.39-0.56 
0.53 
0.44-0.69 
*
0.47 
0.42-0.62 
0.53 
0.39-0.66 
 * * 
Eosinophils [103/μL] 
0.11 
0.09-0.17 
0.14 
0.09-0.20 
 
0.15 
0.07-0.22 
0.15 
0.08-0.29 
*
0.23 
0.17-0.39 
0.20 
0.14-0.29 
* *  
Basophils [103/μL] 
0.02 
0.02-0.03 
0.02 
0.01-0.03 
 
0.02 
0.02-0.03 
0.03 
0.02-0.04 
 
0.03 
0.03-0.48 
0.03 
0.02-0.03 
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sRI-TNFα [pg/mL] 
552 
498-614 
332 
297-412 
*
515 
300-732 
394 
312-514 
 
455 
328-577 
322 
265-367 
*  * 
sRIITNFα [pg/mL] 
361 
333-428 
1295 
411-1789 
*
458 
376-2095 
1598.5 
1211-2053 
*
439 
340-2140 
1117 
412-1970 
 *  
TNFα [pg/mL]a 
565 
282-755 
670 
330-1468 
 
516 
225-894 
1135 
641-2346 
*
724 
430-856 
725 
369-1793 
   
IL8 [pg/mL]a 
4760 
3670-8180 
9387.5 
6645-18675 
*
4850 
3187-8845 
8817.5 
5494-24593 
*
5400 
2080-10700 
13325 
8563-21263 
*   
IL10 [pg/mL]b 
24.0 
8.0-67.0 
28.5 
13.8-58.0 
 
20.5 
0.5-60.0 
42.0 
24.0-119.5 
 
0.5 
0.5-38.0 
15.0 
1.1-33.8 
  * 
            
D-dimer [ng/mL] 
126 
75-170 
146 
90-215 
*
176 
98-286 
330 
155-534 
*
164 
117-192 
179 
128-285 
  * 
PFA-100 C-EPI CT [s] 
127 
111-163 
114 
104-130 
*
301 
170-301 
173 
118-301 
*
117.5 
106-143 
123.5 
99-161 
 * * 
PFA-100 C-ADP CT [s] 
91 
80-104 
81 
72-93 
*
83 
72-108 
77 
68-98 
 
82 
70-97 
84 
75-98 
   
vWF [%] 
112 
89-146 
112 
81-141 
 
141 
92-208 
122 
95-193 
*
118 
80-141 
106.5 
76-134 
   
F1+ 2 [pmol/L] 
150 
127-200 
118 
108-141 
*
150 
119-193 
113 
96-158 
*
140 
120-193 
139 
106-220 
   
tPA [ng/mL] 
6 
3-9 
4 
4-7 
 
6 
5-9 
7 
4-9 
 
6 
4-9 
5 
4-8 
   
Fibrinogen [mg/dL] 
393 
342-461 
395 
342-443 
 
408 
372-544 
389 
357-481 
*
480 
413-543 
442 
373-504 
   
INR 
1.0 
0.9-1.0 
1.1 
1.0-1.1 
*
1.1 
1.0-1.1 
1.1 
1.1-1.2 
*
1.0 
1.0-1.1 
1.1 
1.0-1.2 
* *  
aPTT [s] 
29.60 
27.20-32.20 
29.30 
27.20-31.10 
 
31.10 
28.40-33.70 
30.65 
27.75-32.52 
 
30.70 
28.60-32.70 
30.50 
28.92-32.72 
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Table 7 Changes in monocytes number per an interquartile range increase in 24 hours average PM exposure (model adjusted for: age, gender, BMI, 
statins, FANS, temperature and relative humidity) 
 
 Healthy (n.27)   Heart (n.34)   Lung  (n.21) 
 
% change 
estimated 
regresison 
coefficient  
95% C.I. p-Value   
% change 
estimated 
regresison 
coefficient 
95% C.I. p-Value   
% change 
estimated 
regresison 
coefficient 
95% C.I. p-Value
PM 0, 5 0,61 -11,63 12,86 0,92  7,90 -0,96 16,76 0,08  -17,29 -29,92 -4,67 0,01 
PM1 -0,33 -12,11 11,45 0,95  7,85 -0,71 16,41 0,07  -14,94 -25,69 -4,20 0,01 
PM2, 5 0,33 -11,09 11,75 0,95  7,55 -0,57 15,66 0,07  -14,17 -24,40 -3,94 0,01 
PM 10 1,11 -11,78 13,99 0,86  7,90 -0,47 16,28 0,06  -14,73 -25,85 -3,62 0,01 
UFP 0,02-1 -2,34 -15,55 10,86 0,72  1,94 -6,55 10,43 0,65  1,01 -20,20 22,23 0,92 
FP 0,3-0,5 -3,32 -14,17 7,52 0,54  5,42 -2,85 13,69 0,19  -14,45 -25,84 -3,05 0,02 
FP 0,5-1 -2,94 -9,75 3,87 0,38  5,03 -1,36 11,42 0,12  -15,09 -24,13 -6,06 0,00 
FP 1-2,5 0,33 -10,67 11,33 0,95  3,29 -3,94 10,53 0,36  -18,06 -25,19 -10,94 0,00 
CP 2,5-5 -0,84 -13,66 11,98 0,89  2,60 -4,66 9,86 0,48  -4,58 -15,65 6,48 0,40 
CP 5-10 -3,47 -12,76 5,82 0,45  2,88 -4,04 9,80 0,41  4,79 -4,47 14,05 0,29 
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Table 8 Changes in lymphocytes number per an interquartile range increase in 24 hours average PM exposure (model adjusted for: age, gender, BMI, 
statins, FANS, temperature and relative humidity) 
 
 Healthy (n.27)   Heart (n.34)   Lung  (n.21) 
 
% change 
estimated 
regresison 
coefficient 
95% C.I. p-Value   
% change 
estimated 
regresison 
coefficient 
95% C.I. p-Value   
% change 
estimated 
regresison 
coefficient 
95% C.I. p-Value 
PM 0, 5 9,02 3.58 14.46 0,00  -2,48 -9.41 4.44 0,47  -5,06 -11.90 1.78 0,14 
PM1 9,08 3.92 14.23 0,00  -2,09 -8.86 4.68 0,54  -1,25 -8.01 5.51 0,70 
PM2, 5 8,55 3.47 13.64 0,00  -1,51 -7.95 4.93 0,64  -1,77 -8.15 4.62 0,57 
PM 10 8,71 2.63 14.80 0,01  -0,96 -7.64 5.72 0,77  -2,44 -9.25 4.37 0,46 
UFP 0,02-1  5,68 -0.67 12.03 0,08  0,95 -9.41 4.44 0,76  2,54 -11.90 1.78 0,61 
FP 0,3-0,5 5.68 2.62 12.66 0,00  0.95 -7.57 5.57 0,76  -2.54 -11.48 -0.36 0,04 
FP 0,5-1 7.64 1.69 7.85 0,00  -1.00 -5.52 5.07 0,93  -5.92 -8.61 1.50 0,16 
FP 1-2,5 4.77 -3.59 7.78 0,46  -0.22 -8.14 2.39 0,27  -3.56 -9.91 -0.90 0,02 
CP 2,5-5 2.10 -12.13 1.05 0,10  -2.87 -8.82 2.55 0,27  -5.40 -8.05 1.72 0,19 
CP 5-10 -5.54 -8.38 1.56 0,17  -3.13 -4.44 6.38 0,72  -3.16 -3.13 5.56 0,56 
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Table 9 Changes in erythrocytes number per an interquartile range increase in 24 hours average PM exposure (model adjusted for: age, gender, BMI, 
FANS, temperature and relative humidity) 
 
 Healthy (n.27)   Heart (n.34)   Lung  (n.21) 
 
% change 
estimated 
regresison 
coefficient 
95% C.I. p-Value  
% change 
estimated 
regresison 
coefficient 
95% C.I. p-Value  
% change 
estimated 
regresison 
coefficient 
95% C.I. p-Value 
PM 0, 5 -0.09 -2.19 2.00 0.93  1.42 -0.65 3.49 0.17  -0.89 -3.42 1.65 0.48 
PM1 0.16 -1.85 2.17 0.87  1.31 -0.71 3.33 0.20  -1.54 -3.49 0.42 0.12 
PM2, 5 0.25 -1.70 2.19 0.80  1.15 -0.76 3.07 0.23  -1.30 -3.17 0.58 0.17 
PM 10 0.33 -1.90 2.57 0.76  0.85 -1.17 2.87 0.40  -1.14 -3.17 0.88 0.25 
UFP 0,02-1 -1.26 -3.49 0.96 0.25  0.47 -1.50 2.43 0.63  1.35 -2.50 5.20 0.47 
FP 0,3-0,5 -0.09 -1.96 1.77 0.92  2.14 0.31 3.97 0.02  -0.51 -2.74 1.73 0.64 
FP 0,5-1 0.21 -0.92 1.35 0.70  1.02 -0.50 2.55 0.18  -0.78 -2.72 1.16 0.41 
FP 1-2,5 1.45 -0.31 3.22 0.10  -0.54 -2.21 1.12 0.51  -1.59 -3.34 0.16 0.07 
CP 2,5-5 -1.34 -3.52 0.84 0.22  -0.61 -2.39 1.16 0.49  0.74 -0.97 2.46 0.37 
CP 5-10 -1.28 -2.89 0.34 0.12  1.90 0.48 3.31 0.01  1.15 -0.28 2.59 0.11 
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Table 10 Changes in platelets number per an interquartile range increase in 24 hours average PM exposure (model adjusted for: age, gender, BMI, anti-
clotting therapy, temperature and relative humidity) 
 
 Healthy (n.27)   Heart (n.34)   Lung  (n.21) 
 
% change 
estimated 
regresison 
coefficient 
95% C.I. p-Value  
% change 
estimated 
regresison 
coefficient 
95% C.I. p-Value  
% change 
estimated 
regresison 
coefficient 
95% C.I. p-Value 
PM 0, 5 -1.80 -6.47 2.87 0.43  6.77 -0.84 14.38 0.08  -1.50 -8.23 5.22 0.65 
PM1 -1.42 -5.90 3.06 0.52  6.25 -1.18 13.69 0.10  -2.06 -7.55 3.42 0.44 
PM2, 5 -1.52 -5.87 2.83 0.48  5.51 -1.59 12.61 0.12  -1.62 -6.80 3.56 0.52 
PM 10 -2.38 -7.36 2.60 0.34  5.29 -2.07 12.65 0.15  -1.28 -6.71 4.16 0.63 
UFP 0,02-1 -1.93 -6.86 2.99 0.43  5.19 -1.83 12.20 0.14  -8.01 -16.72 0.69 0.07 
FP 0,3-0,5 -0.40 -4.58 3.79 0.85  5.61 -1.52 12.75 0.12  0.12 -5.64 5.87 0.97 
FP 0,5-1 0.52 -2.01 3.06 0.67  2.60 -3.19 8.39 0.37  0.13 -4.87 5.13 0.96 
FP 1-2,5 0.36 -3.63 4.34 0.86  0.11 -6.10 6.33 0.97  0.88 -3.86 5.62 0.70 
CP 2,5-5 -3.36 -8.26 1.54 0.17  2.01 -4.36 8.37 0.53  2.29 -1.52 6.09 0.22 
CP 5-10 -1.36 -5.01 2.28 0.45  5.19 -0.63 11.01 0.08  0.47 -3.01 3.95 0.78 
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Table 11 Changes closure time PFA 100 C-EPI per an interquartile range increase in 24 hours average PM exposure (model adjusted for: for sex, age, 
body mass index, anti-clotting therapy, temperature and relative humidity) 
 
 Healthy (n.27)   Heart (n.34)   Lung  (n.21) 
 
% change 
estimated 
regresison 
coefficient 
95% C.I. p-Value  
% change 
estimated 
regresison 
coefficient 
95% C.I. p-Value  
% change 
estimated 
regresison 
coefficient 
95% C.I. p-Value 
PM 0, 5 -9.37 -19.17 1.61 0.09  -17.85 -30.29 -3.20 0.02  -1.10 -15.81 16.19 0.89 
PM1 -10.04 -19.30 0.27 0.06  -17.84 -29.84 -3.79 0.02  2.33 -10.78 17.36 0.73 
PM2, 5 -9.45 -18.51 0.61 0.06  -16.69 -28.33 -3.18 0.02  2.18 -10.12 16.18 0.73 
PM 10 -6.40 -17.05 5.61 0.27  -16.76 -28.80 -2.68 0.02  2.77 -10.11 17.49 0.68 
UFP 0,02-1 -2.86 -14.76 10.70 0.66  -6.34 -19.73 9.29 0.40  15.09 -7.13 42.63 0.19 
FP 0,3-0,5 -9.63 -18.24 -0.11 0.05  -18.90 -29.83 -6.25 0.01  -2.56 -16.83 14.17 0.74 
FP 0,5-1 -6.81 -12.61 -0.62 0.03  -14.98 -23.70 -5.27 0.00  0.44 -12.45 15.23 0.95 
FP 1-2,5 -6.01 -15.39 4.40 0.24  -18.94 -28.87 -7.62 0.00  -5.53 -17.31 7.93 0.39 
CP 2,5-5 -14.71 -29.10  -1.92 0.02  -12.15 -22.62 -0.25 0.05  -1.14 -12.10 11.19 0.84 
CP 5-10 -11.26 -21.19  -2.14 0.02  -5.86 -17.27 7.12 0.35  1.85 -8.31 13.12 0.72 
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Table 12 Changes closure time tPA per an interquartile range increase in 24 hours average PM exposure (model adjusted for: for sex, age, body mass 
index, anti-clotting therapy, temperature and relative humidity) 
 
 Healthy (n.27)   Heart (n.34)   Lung  (n.21) 
 
% change 
estimated 
regresison 
coefficient 
95% C.I. p-Value  
% change 
estimated 
regresison 
coefficient 
95% C.I. p-Value  
% change 
estimated 
regresison 
coefficient 
95% C.I. p-Value 
PM 0, 5 22.59 -3,20 55,25 0.09  7.32 -10,60 28,84 0.44  -0.76 -20,13 23,30 0.94 
PM1 22.47 -2,12 53,24 0.07  5.79 -10,03 24,38 0.49  0.50 -17,21 21,99 0.96 
PM2, 5 20.85 -2,71 50,11 0.08  5.31 -9,70 22,83 0.50  1.13 -15,71 21,33 0.90 
PM 10 23.29 -3,37 57,31 0.09  6.26 -9,58 24,87 0.45  2.48 -15,36 24,07 0.80 
UFP 0,02-1 24.42 -3,19 59,91 0.09  3.59 -11,58 21,37 0.66  -5.42 -30,42 28,56 0.71 
FP 0,3-0,5 22.38 -0,45 50,45 0.05  5.74 -8,77 22,56 0.45  3.96 -14,92 27,02 0.69 
FP 0,5-1 12.83 -1,06 28,66 0.07  9.08 -1,76 21,12 0.10  5.34 -11,40 25,25 0.54 
FP 1-2,5 5.28 -15,07 30,49 0.63  6.53 -8,38 23,85 0.40  -11.19 -24,65 4,68 0.15 
CP 2,5-5 -16.83 -35,54 7,30 0.15  -2.11 -14,15 11,63 0.75  6.58 -8,21 23,75 0.38 
CP 5-10 -11.96 -27,06 6,26 0.18  -1.58 -13,00 11,35 0.80  16.00 3,43 30,09 0.01 
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